



(86) Date de dépôt PCT/PCT Filing Date: 2011/06/30
(87) Date publication PCT/PCT Publication Date: 2012/01/05
(85) Entrée phase nationale/National Entry: 2012/12/18
(86) N° demande PCT/PCT Application No.: US 2011/042499
(87) N° publication PCT/PCT Publication No.: 2012/003262
(30) Priorité/Priority: 2010/07/01 (US61/360,743)

(51) Cl.Int./Int.Cl. *C07D 495/04* (2006.01),
A61K 31/4365 (2006.01), *A61K 31/444* (2006.01),
A61K 31/52 (2006.01), *A61P 29/00* (2006.01),
A61P 35/00 (2006.01), *C07D 519/00* (2006.01)
(71) Demandeur/Applicant:
AMGEN INC., US
(72) Inventeur/Inventor:
LUCAS, BRIAN, US
(74) Agent: SMART & BIGGAR

(54) Titre : COMPOSES HETEROCYCLIQUES ET LEUR UTILISATION COMME INHIBITEURS DE L'ACTIVITE PI3 K
(54) Title: HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY

(57) **Abrégé/Abstract:**

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 January 2012 (05.01.2012)

PCT

(10) International Publication Number
WO 2012/003262 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) *A61K 31/4743* (2006.01)
C07D 487/04 (2006.01) *A61P 29/00* (2006.01)
C07D 519/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2011/042499

(22) International Filing Date:

30 June 2011 (30.06.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/360,743 1 July 2010 (01.07.2010) US

(71) **Applicant** (*for all designated States except US*): **AM-GEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).(72) **Inventor; and**(75) **Inventor/Applicant** (*for US only*): **LUCAS, Brian** [US/US]; 133 10th Avenue, San Francisco, California 94118 (US).(74) **Agent: PERSON, Richard, V.**; Amgen Inc., M/s 28-2-c, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**Declarations under Rule 4.17:**— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))***Published:**— *with international search report (Art. 21(3))*(54) **Title:** HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY(57) **Abstract:** Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

WO 2012/003262 A1

- 1 -

HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3 K ACTIVITY

This application claims the benefit of U.S. Provisional Application No. 61/360,743, filed July 1, 2010, which is hereby incorporated by reference.

The present invention relates generally to phosphatidylinositol 3-kinase (PI3K) enzymes, and more particularly to selective inhibitors of PI3K activity and to methods of using such materials.

BACKGROUND OF THE INVENTION

Cell signaling via 3'-phosphorylated phosphoinositides has been implicated in a variety of cellular processes, e.g., malignant transformation, growth factor signaling, inflammation, and immunity (see Rameh et al., J. Biol Chem, 274:8347-8350 (1999) for a review). The enzyme responsible for generating these phosphorylated signaling products, phosphatidylinositol 3-kinase (PI 3-kinase; PI3K), was originally identified as an activity associated with viral oncoproteins and growth factor receptor tyrosine kinases that phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at the 3'-hydroxyl of the inositol ring (Panayotou et al., Trends Cell Biol 2:358-60 (1992)).

The levels of phosphatidylinositol-3,4,5-triphosphate (PIP3), the primary product of PI 3-kinase activation, increase upon treatment of cells with a variety of stimuli. This includes signaling through receptors for the majority of growth factors and many inflammatory stimuli, hormones, neurotransmitters and antigens, and thus the activation of PI3Ks represents one, if not the most prevalent, signal transduction events associated with mammalian cell surface receptor activation (Cantley, Science 296:1655-1657 (2002); Vanhaesebroeck et al. Annu.Rev.Biochem, 70: 535-602 (2001)). PI 3-kinase activation, therefore, is involved in a wide range of cellular responses including cell growth, migration, differentiation, and apoptosis (Parker et al., Current Biology, 5:577-99 (1995); Yao et al., Science, 267:2003-05 (1995)). Though the downstream targets of phosphorylated lipids generated following PI 3-kinase activation have not been fully characterized, it is known that pleckstrin-homology (PH) domain- and FYVE-finger domain-containing proteins are activated when binding to various phosphatidylinositol lipids (Sternmark et al., J Cell Sci, 112:4175-83 (1999);

- 2 -

.Lemmon et al., Trends Cell Biol, 7:237-42 (1997)). Two groups of PH-domain containing PI3K effectors have been studied in the context of immune cell signaling, members of the tyrosine kinase TEC family and the serine/threonine kinases of the AGC family. Members of the Tec family containing PH domains with apparent selectivity for PtdIns (3,4,5)P₃ include Tec, Btk, Itk and Etk. Binding of PH to PIP₃ is critical for tyrosine kinase activity of the Tec family members (Schaeffer and Schwartzberg, Curr.Opin.Immunol. 12: 282-288 (2000)) AGC family members that are regulated by PI3K include the phosphoinositide-dependent kinase (PDK1), AKT (also termed PKB) and certain isoforms of protein kinase C (PKC) and S6 kinase. There are three isoforms of AKT and activation of AKT is strongly associated with PI3K- dependent proliferation and survival signals. Activation of AKT depends on phosphorylation by PDK1, which also has a 3-phosphoinositide-selective PH domain to recruit it to the membrane where it interacts with AKT. Other important PDK1 substrates are PKC and S6 kinase (Deane and Fruman, Annu.Rev.Immunol. 22_563-598 (2004)). In vitro, some isoforms of protein kinase C (PKC) are directly activated by PIP₃. (Burgering et al., Nature, 376:599-602 (1995)).

Presently, the PI 3-kinase enzyme family has been divided into three classes based on their substrate specificities. Class I PI3Ks can phosphorylate phosphatidylinositol (PI), phosphatidylinositol-4-phosphate, and phosphatidylinositol-4,5-biphosphate (PIP₂) to produce phosphatidylinositol-3-phosphate (PIP), phosphatidylinositol-3,4-biphosphate, and phosphatidylinositol-3,4,5-triphosphate, respectively. Class II PI3Ks phosphorylate PI and phosphatidylinositol-4-phosphate, whereas Class III PI3Ks can only phosphorylate PI.

The initial purification and molecular cloning of PI 3-kinase revealed that it was a heterodimer consisting of p85 and p110 subunits (Otsu et al., Cell, 65:91-104 (1991); Hiles et al., Cell, 70:419-29 (1992)). Since then, four distinct Class I PI3Ks have been identified, designated PI3K α , β , δ , and γ , each consisting of a distinct 110 kDa catalytic subunit and a regulatory subunit. More specifically, three of the catalytic subunits, i.e., p110 α , p110 β and p110 δ , each interact with the same regulatory subunit, p85; whereas p110 γ interacts with a distinct regulatory

- 3 -

subunit, p101. As described below, the patterns of expression of each of these PI3Ks in human cells and tissues are also distinct. Though a wealth of information has been accumulated in recent past on the cellular functions of PI 3-kinases in general, the roles played by the individual isoforms are not fully understood.

5 Cloning of bovine p110 α has been described. This protein was identified as related to the *Saccharomyces cerevisiae* protein: Vps34p, a protein involved in vacuolar protein processing. The recombinant p110 α product was also shown to associate with p85 α , to yield a PI3K activity in transfected COS-1 cells. See Hiles et al., *Cell*, 70, 419-29 (1992).

10 The cloning of a second human p110 isoform, designated p110 β , is described in Hu et al., *Mol Cell Biol*, 13:7677-88 (1993). This isoform is said to associate with p85 in cells, and to be ubiquitously expressed, as p110 β mRNA has been found in numerous human and mouse tissues as well as in human umbilical vein endothelial cells, Jurkat human leukemic T cells, 293 human embryonic
15 kidney cells, mouse 3T3 fibroblasts, HeLa cells, and NBT2 rat bladder carcinoma cells. Such wide expression suggests that this isoform is broadly important in signaling pathways.

 Identification of the p110 δ isoform of PI 3-kinase is described in Chantry et al., *J Biol Chem*, 272:19236-41 (1997). It was observed that the human p110 δ
20 isoform is expressed in a tissue-restricted fashion. It is expressed at high levels in lymphocytes and lymphoid tissues and has been shown to play a key role in PI 3-kinase-mediated signaling in the immune system (Al-Alwan et al. *J Biol Chem*, 282: 2328-2335 (2007); Okkenhaug et al. *J Biol Chem*, 281: 5122-5128 (2006); Lee et al. *PNAS*, 103: 1289-1294 (2006)). P110 δ has also been shown to be expressed at lower levels in
25 breast cells, melanocytes and endothelial cells (Vogt et al. *Virology*, 344: 131-138 (2006) and has since been implicated in conferring selective migratory properties to breast cancer cells (Sawyer et al. *Cancer Res.* 63:1667-1675 (2003)). Details concerning the P110 δ isoform also can be found in U.S. Pat. Nos. 5,858,753; 5,822,910; and 5,985,589. See also, Vanhaesebroeck et al., *Proc Nat. Acad Sci*
30 USA, 94:4330-5 (1997), and international publication WO 97/46688.

- 4 -

In each of the PI3K α , β , and δ subtypes, the p85 subunit acts to localize PI 3-kinase to the plasma membrane by the interaction of its SH2 domain with phosphorylated tyrosine residues (present in an appropriate sequence context) in target proteins (Rameh et al., Cell, 83:821-30 (1995)). Five isoforms of p85 have
5 been identified (p85 α , p85 β , p55 γ , p55 α and p50 α) encoded by three genes. Alternative transcripts of Pik3r1 gene encode the p85 α , p55 α and p50 α proteins (Deane and Fruman, Annu.Rev.Immunol. 22: 563-598 (2004)). p85 α is ubiquitously expressed while p85 β , is primarily found in the brain and lymphoid tissues (Volinia et al., Oncogene, 7:789-93 (1992)). Association of the p85 subunit
10 to the PI 3-kinase p110 α , β , or δ catalytic subunits appears to be required for the catalytic activity and stability of these enzymes. In addition, the binding of Ras proteins also upregulates PI 3-kinase activity.

The cloning of p110 γ revealed still further complexity within the PI3K family of enzymes (Stoyanov et al., Science, 269:690-93 (1995)). The p110 γ
15 isoform is closely related to p110 α and p110 β (45-48% identity in the catalytic domain), but as noted does not make use of p85 as a targeting subunit. Instead, p110 γ binds a p101 regulatory subunit that also binds to the $\beta\gamma$ subunits of heterotrimeric G proteins. The p101 regulatory subunit for PI3K γ was originally cloned in swine, and the human ortholog identified subsequently
20 (Krugmann et al., J Biol Chem, 274:17152-8 (1999)). Interaction between the N-terminal region of p101 with the N-terminal region of p110 γ is known to activate PI3K γ through G $\beta\gamma$. Recently, a p101-homologue has been identified, p84 or p87^{PIKAP} (PI3K γ adapter protein of 87 kDa) that binds p110 γ (Voigt et al. JBC, 281: 9977-9986 (2006), Suire et al. Curr.Biol. 15: 566-570 (2005)). p87^{PIKAP} is
25 homologous to p101 in areas that bind p110 γ and G $\beta\gamma$ and also mediates activation of p110 γ downstream of G-protein-coupled receptors. Unlike p101, p87^{PIKAP} is highly expressed in the heart and may be crucial to PI3K γ cardiac function.

A constitutively active PI3K polypeptide is described in international
30 publication WO 96/25488. This publication discloses preparation of a chimeric fusion protein in which a 102-residue fragment of p85 known as the inter-SH2

- 5 -

(iSH2) region is fused through a linker region to the N-terminus of murine p110. The p85 iSH2 domain apparently is able to activate PI3K activity in a manner comparable to intact p85 (Klippel et al., Mol Cell Biol, 14:2675-85 (1994)).

Thus, PI 3-kinases can be defined by their amino acid identity or by their activity. Additional members of this growing gene family include more distantly related lipid and protein kinases including Vps34 TOR1, and TOR2 of *Saccharomyces cerevisiae* (and their mammalian homologs such as FRAP and mTOR), the ataxia telangiectasia gene product (ATR) and the catalytic subunit of DNA-dependent protein kinase (DNA-PK). See generally, Hunter, Cell, 83:1-4 (1995).

PI 3-kinase is also involved in a number of aspects of leukocyte activation. A p85-associated PI 3-kinase activity has been shown to physically associate with the cytoplasmic domain of CD28, which is an important costimulatory molecule for the activation of T-cells in response to antigen (Pages et al., Nature, 369:327-29 (1994); Rudd, Immunity, 4:527-34 (1996)). Activation of T cells through CD28 lowers the threshold for activation by antigen and increases the magnitude and duration of the proliferative response. These effects are linked to increases in the transcription of a number of genes including interleukin-2 (IL2), an important T cell growth factor (Fraser et al., Science, 251:313-16 (1991)). Mutation of CD28 such that it can no longer interact with PI 3-kinase leads to a failure to initiate IL2 production, suggesting a critical role for PI 3-kinase in T cell activation.

Specific inhibitors against individual members of a family of enzymes provide invaluable tools for deciphering functions of each enzyme. Two compounds, LY294002 and wortmannin, have been widely used as PI 3-kinase inhibitors. These compounds, however, are nonspecific PI3K inhibitors, as they do not distinguish among the four members of Class I PI 3-kinases. For example, the IC₅₀ values of wortmannin against each of the various Class I PI 3-kinases are in the range of 1-10nM. Similarly, the IC₅₀ values for LY294002 against each of these PI 3-kinases is about 1μM (Fruman et al., Ann Rev Biochem, 67:481-507 (1998)). Hence, the utility of these compounds in studying the roles of individual Class I PI 3-kinases is limited.

- 6 -

Based on studies using wortmannin, there is evidence that PI 3-kinase function also is required for some aspects of leukocyte signaling through G-protein coupled receptors (Thelen et al., Proc Natl Acad Sci USA, 91:4960-64 (1994)). Moreover, it has been shown that wortmannin and LY294002 block
5 neutrophil migration and superoxide release. However, inasmuch as these compounds do not distinguish among the various isoforms of PI3K, it remains unclear from these studies which particular PI3K isoform or isoforms are involved in these phenomena and what functions the different Class I PI3K enzymes perform in both normal and diseased tissues in general. The co-expression of
10 several PI3K isoforms in most tissues has confounded efforts to segregate the activities of each enzyme until recently.

The separation of the activities of the various PI3K isozymes has been advanced recently with the development of genetically manipulated mice that allowed the study of isoform-specific knock-out and kinase dead knock-in mice
15 and the development of more selective inhibitors for some of the different isoforms. P110 α and p110 β knockout mice have been generated and are both embryonic lethal and little information can be obtained from these mice regarding the expression and function of p110 alpha and beta (Bi et al. Mamm.Genome, 13:169-172 (2002); Bi et al. J.Biol.Chem. 274:10963-10968 (1999)). More
20 recently, p110 α kinase dead knock in mice were generated with a single point mutation in the DFG motif of the ATP binding pocket (p110 α D^{933A}) that impairs kinase activity but preserves mutant p110 α kinase expression. In contrast to knock out mice, the knockin approach preserves signaling complex stoichiometry, scaffold functions and mimics small molecule approaches more realistically than
25 knock out mice. Similar to the p110 α KO mice, p110 α D^{933A} homozygous mice are embryonic lethal. However, heterozygous mice are viable and fertile but display severely blunted signaling via insulin-receptor substrate (IRS) proteins, key mediators of insulin, insulin-like growth factor-1 and leptin action. Defective responsiveness to these hormones leads to hyperinsulinaemia, glucose intolerance,
30 hyperphagia, increase adiposity and reduced overall growth in heterozygotes (Foukas, et al. Nature, 441: 366-370 (2006)). These studies revealed a defined,

- 7 -

non-redundant role for p110 α as an intermediate in IGF-1, insulin and leptin signaling that is not substituted for by other isoforms. We will have to await the description of the p110 β kinase-dead knock in mice to further understand the function of this isoform (mice have been made but not yet published;

5 Vanhaesebroeck).

P110 γ knock out and kinase-dead knock in mice have both been generated and overall show similar and mild phenotypes with primary defects in migration of cells of the innate immune system and a defect in thymic development of T cells (Li et al. Science, 287: 1046-1049 (2000), Sasaki et al. Science, 287: 1040-1046
10 (2000), Patrucco et al. Cell, 118: 375-387 (2004)).

Similar to p110 γ , PI3K delta knock out and kinase-dead knock-in mice have been made and are viable with mild and like phenotypes. The p110 δ^{D910A} mutant knock in mice demonstrated an important role for delta in B cell development and function, with marginal zone B cells and CD5+ B1 cells nearly
15 undetectable, and B- and T cell antigen receptor signaling (Clayton et al. J.Exp.Med. 196:753-763 (2002); Okkenhaug et al. Science, 297: 1031-1034 (2002)). The p110 δ^{D910A} mice have been studied extensively and have elucidated the diverse role that delta plays in the immune system. T cell dependent and T cell independent immune responses are severely attenuated in p110 δ^{D910A} and
20 secretion of TH1 (INF- γ) and TH2 cytokine (IL-4, IL-5) are impaired (Okkenhaug et al. J.Immunol. 177: 5122-5128 (2006)). A human patient with a mutation in p110 δ has also recently been described. A taiwanese boy with a primary B cell immunodeficiency and a gamma-hypoglobulinemia of previously unknown aetiology presented with a single base-pair substitution, m.3256G to A in codon
25 1021 in exon 24 of p110 δ . This mutation resulted in a mis-sense amino acid substitution (E to K) at codon 1021, which is located in the highly conserved catalytic domain of p110 δ protein. The patient has no other identified mutations and his phenotype is consistent with p110 δ deficiency in mice as far as studied. (Jou et al. Int.J.Immunogenet. 33: 361-369 (2006)).

- 8 -

Isoform-selective small molecule compounds have been developed with varying success to all Class I PI3 kinase isoforms (Ito et al. J. Pharm. Exp. Therapeut., 321:1-8 (2007)). Inhibitors to alpha are desirable because mutations in p110 α have been identified in several solid tumors; for example, an amplification
5 mutation of alpha is associated with 50% of ovarian, cervical, lung and breast cancer and an activation mutation has been described in more than 50% of bowel and 25% of breast cancers (Hennessy et al. Nature Reviews, 4: 988-1004 (2005)). Yamanouchi has developed a compound YM-024 that inhibits alpha and delta equipotently and is 8- and 28-fold selective over beta and gamma respectively (Ito
10 et al. J.Pharm.Exp.Therapeut., 321:1-8 (2007)).

P110 β is involved in thrombus formation (Jackson et al. Nature Med. 11: 507-514 (2005)) and small molecule inhibitors specific for this isoform are thought after for indication involving clotting disorders (TGX-221: 0.007 μ M on beta; 14-fold selective over delta, and more than 500-fold selective over gamma
15 and alpha) (Ito et al. J.Pharm.Exp.Therapeut., 321:1-8 (2007)).

Selective compounds to p110 γ are being developed by several groups as immunosuppressive agents for autoimmune disease (Rueckle et al. Nature Reviews, 5: 903-918 (2006)). Of note, AS 605240 has been shown to be efficacious in a mouse model of rheumatoid arthritis (Camps et al. Nature
20 Medicine, 11: 936-943 (2005)) and to delay onset of disease in a model of systemic lupus erythematosus (Barber et al. Nature Medicine, 11: 933-935 (205)).

Delta-selective inhibitors have also been described recently. The most selective compounds include the quinazolinone purine inhibitors (PIK39 and IC87114). IC87114 inhibits p110 δ in the high nanomolar range (triple digit) and
25 has greater than 100-fold selectivity against p110 α , is 52 fold selective against p110 β but lacks selectivity against p110 γ (approx. 8-fold). It shows no activity against any protein kinases tested (Knight et al. Cell, 125: 733-747 (2006)). Using delta-selective compounds or genetically manipulated mice (p110 δ^{D910A}) it was shown that in addition to playing a key role in B and T cell activation, delta is also
30 partially involved in neutrophil migration and primed neutrophil respiratory burst

- 9 -


and leads to a partial block of antigen-IgE mediated mast cell degranulation (Condliffe et al. Blood, 106: 1432-1440 (2005); Ali et al. Nature, 431: 1007-1011 (2002)). Hence p110 δ is emerging as an important mediator of many key inflammatory responses that are also known to participate in aberrant inflammatory conditions, including but not limited to autoimmune disease and allergy. To support this notion, there is a growing body of p110 δ target validation data derived from studies using both genetic tools and pharmacologic agents. Thus, using the delta-selective compound IC 87114 and the p110 δ^{D910A} mice, Ali et al. (Nature, 431: 1007-1011 (2002)) have demonstrated that delta plays a critical role in a murine model of allergic disease. In the absence of functional delta, passive cutaneous anaphylaxis (PCA) is significantly reduced and can be attributed to a reduction in allergen-IgE induced mast cell activation and degranulation. In addition, inhibition of delta with IC 87114 has been shown to significantly ameliorate inflammation and disease in a murine model of asthma using ovalbumin-induced airway inflammation (Lee et al. FASEB, 20: 455-465 (2006)). These data utilizing compound were corroborated in p110 δ^{D910A} mutant mice using the same model of allergic airway inflammation by a different group (Nashed et al. Eur.J.Immunol. 37:416-424 (2007)).

There exists a need for further characterization of PI3K δ function in inflammatory and auto-immune settings. Furthermore, our understanding of PI3K δ requires further elaboration of the structural interactions of p110 δ , both with its regulatory subunit and with other proteins in the cell. There also remains a need for more potent and selective or specific inhibitors of PI3K delta, in order to avoid potential toxicology associated with activity on isozymes p110 alpha (insulin signaling) and beta (platelet activation). In particular, selective or specific inhibitors of PI3K δ are desirable for exploring the role of this isozyme further and for development of superior pharmaceuticals to modulate the activity of the isozyme.

- 10 -

Summary

The present invention comprises a new class of compounds having the general formula




5

which are useful to inhibit the biological activity of human PI3K δ . Another aspect of the invention is to provide compounds that inhibit PI3K δ selectively while having relatively low inhibitory potency against the other PI3K isoforms. Another aspect of the invention is to provide methods of characterizing the function of human PI3K δ . Another aspect of the invention is to provide methods of selectively modulating human PI3K δ activity, and thereby promoting medical treatment of diseases mediated by PI3K δ dysfunction. Other aspects and advantages of the invention will be readily apparent to the artisan having ordinary skill in the art.

15 **Detailed Description**

One aspect of the invention relates to compounds having the structure:



or any pharmaceutically-acceptable salt thereof, wherein:

20 X^1 is C(R¹⁰) or N; X^2 is C(R⁶) or N;

- 11 -

X^3 is $C(R^7)$ or N;

X^4 is $C(R^{10})$ or N;

Y is $N(R^8)$, CR^aR^a , S or O;

- R^1 is selected from H, halo, $C_{1-6}alk$, $C_{1-4}haloalk$, cyano, nitro, $-C(=O)R^a$,
 5 $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-OC(=O)NR^aR^a$,
 $-OC(=O)N(R^a)S(=O)_2R^a$, $-OC_{2-6}alkNR^aR^a$, $-OC_{2-6}alkOR^a$, $-SR^a$, $-S(=O)R^a$,
 $-S(=O)_2R^a$, $-S(=O)_2NR^aR^a$, $-S(=O)_2N(R^a)C(=O)R^a$, $-S(=O)_2N(R^a)C(=O)OR^a$,
 $-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$, $-N(R^a)C(=O)OR^a$,
 $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$,
 10 $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$, $-NR^aC_{2-6}alkOR^a$, $-NR^aC_{2-6}alkCO_2R^a$,
 $-NR^aC_{2-6}alkSO_2R^b$, $-CH_2C(=O)R^a$, $-CH_2C(=O)OR^a$, $-CH_2C(=O)NR^aR^a$,
 $-CH_2C(=NR^a)NR^aR^a$, $-CH_2OR^a$, $-CH_2OC(=O)R^a$, $-CH_2OC(=O)NR^aR^a$,
 $-CH_2OC(=O)N(R^a)S(=O)_2R^a$, $-CH_2OC_{2-6}alkNR^aR^a$, $-CH_2OC_{2-6}alkOR^a$, $-CH_2SR^a$,
 $-CH_2S(=O)R^a$, $-CH_2S(=O)_2R^b$, $-CH_2S(=O)_2NR^aR^a$, $-CH_2S(=O)_2N(R^a)C(=O)R^a$,
 15 $-CH_2S(=O)_2N(R^a)C(=O)OR^a$, $-CH_2S(=O)_2N(R^a)C(=O)NR^aR^a$, $-CH_2NR^aR^a$,
 $-CH_2N(R^a)C(=O)R^a$, $-CH_2N(R^a)C(=O)OR^a$, $-CH_2N(R^a)C(=O)NR^aR^a$,
 $-CH_2N(R^a)C(=NR^a)NR^aR^a$, $-CH_2N(R^a)S(=O)_2R^a$, $-CH_2N(R^a)S(=O)_2NR^aR^a$,
 $-CH_2NR^aC_{2-6}alkNR^aR^a$, $-CH_2NR^aC_{2-6}alkOR^a$, $-CH_2NR^aC_{2-6}alkCO_2R^a$ and
 $-CH_2NR^aC_{2-6}alkSO_2R^b$; or R^1 is a direct-bonded, $C_{1-4}alk$ -linked, $OC_{1-2}alk$ -linked,
 20 $C_{1-2}alkO$ -linked, $N(R^a)$ -linked or O-linked saturated, partially-saturated or
 unsaturated 3-, 4-, 5-, 6- or 7-membered monocyclic or 8-, 9-, 10- or 11-
 membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S,
 but containing no more than one O or S atom, substituted by 0, 1, 2 or 3
 substituents independently selected from halo, $C_{1-6}alk$, $C_{1-4}haloalk$, cyano, nitro,
 25 $-C(=O)R^a$, $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$,
 $-OC(=O)NR^aR^a$, $-OC(=O)N(R^a)S(=O)_2R^a$, $-OC_{2-6}alkNR^aR^a$, $-OC_{2-6}alkOR^a$, $-SR^a$,
 $-S(=O)R^a$, $-S(=O)_2R^a$, $-S(=O)_2NR^aR^a$, $-S(=O)_2N(R^a)C(=O)R^a$,
 $-S(=O)_2N(R^a)C(=O)OR^a$, $-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$,
 $-N(R^a)C(=O)OR^a$, $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$,
 30 $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$ and $-NR^aC_{2-6}alkOR^a$, wherein the
 available carbon atoms of the ring are additionally substituted by 0, 1 or 2 oxo or

- 12 -

thioxo groups, and wherein the ring is additionally substituted by 0 or 1 directly bonded, SO₂ linked, C(=O) linked or CH₂ linked group selected from phenyl, pyridyl, pyrimidyl, morpholino, piperazinyl, piperadiny, pyrrolidinyl, cyclopentyl, cyclohexyl all of which are further substituted by 0, 1, 2 or 3 groups selected from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -SR^a, -S(=O)R^a, -S(=O)₂R^a, -S(=O)₂NR^aR^a, -NR^aR^a, and -N(R^a)C(=O)R^a;

R² is selected from a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic or 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or 1 R² substituents, and the ring is additionally substituted by 0, 1, 2 or 3 substituents independently selected from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a, -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a, -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a, -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a, -N(R^a)C(=O)OR^a, -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a, -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a; or R³ is selected from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a, -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a, -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a, -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a, -N(R^a)C(=O)OR^a, -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a, -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a;

R³ is selected from H, halo, nitro, cyano, C₁₋₄alk, OC₁₋₄alk, OC₁₋₄haloalk, NHC₁₋₄alk, N(C₁₋₄alk)C₁₋₄alk, C(=O)NH₂, C(=O)NHC₁₋₄alk, C(=O)N(C₁₋₄alk)C₁₋₄alk, N(H)C(=O)C₁₋₄alk, N(C₁₋₄alk)C(=O)C₁₋₄alk and C₁₋₄haloalk;

- 13 -

R^4 is selected from H, halo, nitro, cyano, $C_{1-4}alk$, $OC_{1-4}alk$, $OC_{1-4}haloalk$, $NHC_{1-4}alk$, $N(C_{1-4}alk)C_{1-4}alk$, $C(=O)NH_2$, $C(=O)NHC_{1-4}alk$, $C(=O)N(C_{1-4}alk)C_{1-4}alk$, $N(H)C(=O)C_{1-4}alk$, $N(C_{1-4}alk)C(=O)C_{1-4}alk$ and $C_{1-4}haloalk$;

R^5 is, independently, in each instance, H, halo, $C_{1-6}alk$, $C_{1-4}haloalk$, or
 5 $C_{1-6}alk$ substituted by 1, 2 or 3 substituents selected from halo, cyano, OH, $OC_{1-4}alk$, $C_{1-4}alk$, $C_{1-3}haloalk$, $OC_{1-4}alk$, NH_2 , $NHC_{1-4}alk$ and $N(C_{1-4}alk)C_{1-4}alk$;
 or both R^5 groups together form a $C_{3-6}spiroalk$ substituted by 0, 1, 2 or 3
 substituents selected from halo, cyano, OH, $OC_{1-4}alk$, $C_{1-4}alk$, $C_{1-3}haloalk$, $OC_{1-4}alk$, NH_2 , $NHC_{1-4}alk$ and $N(C_{1-4}alk)C_{1-4}alk$;

10 R^6 is selected from halo, cyano, OH, $OC_{1-4}alk$, $C_{1-4}alk$, $C_{1-3}haloalk$, $OC_{1-4}alk$, NHR^9 , $N(C_{1-4}alk)C_{1-4}alk$, $-C(=O)OR^a$, $-C(=O)N(R^a)R^a$, $-N(R^a)C(=O)R^b$ and a
 5- or 6-membered saturated or partially saturated heterocyclic ring containing 1, 2
 or 3 heteroatoms selected from N, O and S, wherein the ring is substituted by 0, 1,
 2 or 3 substituents selected from halo, cyano, OH, oxo, $OC_{1-4}alk$, $C_{1-4}alk$, $C_{1-3}haloalk$, $OC_{1-4}alk$, NH_2 , $NHC_{1-4}alk$ and $N(C_{1-4}alk)C_{1-4}alk$;

15 R^7 is selected from H, halo, $C_{1-4}haloalk$, cyano, nitro, $-C(=O)R^a$,
 $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-OC(=O)NR^aR^a$,
 $-OC(=O)N(R^a)S(=O)_2R^a$, $-OC_{2-6}alkNR^aR^a$, $-OC_{2-6}alkOR^a$, $-SR^a$, $-S(=O)R^a$,
 $-S(=O)_2R^a$, $-S(=O)_2NR^aR^a$, $-S(=O)_2N(R^a)C(=O)R^a$, $-S(=O)_2N(R^a)C(=O)OR^a$,
 20 $-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$, $-N(R^a)C(=O)OR^a$,
 $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$,
 $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$, $-NR^aC_{2-6}alkOR^a$ and $C_{1-6}alk$, wherein the
 $C_{1-6}alk$ is substituted by 0, 1 2 or 3 substituents selected from halo, $C_{1-4}haloalk$,
 cyano, nitro, $-C(=O)R^a$, $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-OR^a$,
 25 $-OC(=O)R^a$, $-OC(=O)NR^aR^a$, $-OC(=O)N(R^a)S(=O)_2R^a$, $-OC_{2-6}alkNR^aR^a$,
 $-OC_{2-6}alkOR^a$, $-SR^a$, $-S(=O)R^a$, $-S(=O)_2R^a$, $-S(=O)_2NR^aR^a$, $-S(=O)_2N(R^a)C(=O)R^a$,
 $-S(=O)_2N(R^a)C(=O)OR^a$, $-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$,
 $-N(R^a)C(=O)OR^a$, $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$,
 $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$ and $-NR^aC_{2-6}alkOR^a$, and the $C_{1-6}alk$ is
 30 additionally substituted by 0 or 1 saturated, partially-saturated or unsaturated 5-,
 6- or 7-membered monocyclic rings containing 0, 1, 2, 3 or 4 atoms selected from

- 14 -

N, O and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from halo, nitro, cyano, C₁₋₄alk, OC₁₋₄alk, OC₁₋₄haloalk, NHC₁₋₄alk, N(C₁₋₄alk)C₁₋₄alk and C₁₋₄haloalk; or R⁷ and R⁸ together form a -C=N- bridge wherein the carbon atom is substituted by H, halo, cyano, or a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0, 1, 2, 3 or 4 substituents selected from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a, -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a, -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a, -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a, -N(R^a)C(=O)OR^a, -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a, -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a; or R⁷ and R⁹ together form a -N=C- bridge wherein the carbon atom is substituted by H, halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, OR^a, NR^aR^a, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -S(=O)R^a, -S(=O)₂R^a or -S(=O)₂NR^aR^a;

R⁸ is H, C₁₋₆alk, C(=O)N(R^a)R^a, C(=O)R^b or C₁₋₄haloalk;

R⁹ is H, C₁₋₆alk or C₁₋₄haloalk;

R¹⁰ is independently in each instance H, halo, C₁₋₃alk, C₁₋₃haloalk or cyano;

R¹¹ is selected from H, halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a, -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a, -S(=O)₂R^b, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a, -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a, -N(R^a)C(=O)OR^a, -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a, -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a;

R^a is independently, at each instance, H or R^b; and

- 15 -

R^b is independently, at each instance, phenyl, benzyl or $C_{1-6}alk$, the phenyl, benzyl and $C_{1-6}alk$ being substituted by 0, 1, 2 or 3 substituents selected from halo, $C_{1-4}alk$, $C_{1-3}haloalk$, $-OC_{1-4}alk$, $-NH_2$, $-NHC_{1-4}alk$ and $-N(C_{1-4}alk)C_{1-4}alk$.

In another embodiment, in conjunction with the above and below
5 embodiments, X^1 is N.

In another embodiment, in conjunction with the above and below
embodiments, X^4 is N.

In another embodiment, in conjunction with the above and below
embodiments, X^1 is N and X^4 is N.

10 In another embodiment, in conjunction with the above and below
embodiments, Y is $N(R^8)$.

In another embodiment, in conjunction with the above and below
embodiments, Y is N(H).

In another embodiment, in conjunction with the above and below
15 embodiments, R^1 is a direct-bonded saturated, partially-saturated or unsaturated
5-, 6- or 7-membered monocyclic or 8-, 9-, 10- or 11-membered bicyclic ring
containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more
than one O or S atom, substituted by 0, 1, 2 or 3 substituents independently
selected from halo, $C_{1-6}alk$, $C_{1-4}haloalk$, cyano, nitro, $-C(=O)R^a$, $-C(=O)OR^a$,
20 $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-OC(=O)NR^aR^a$,
 $-OC(=O)N(R^a)S(=O)_2R^a$, $-OC_{2-6}alkNR^aR^a$, $-OC_{2-6}alkOR^a$, $-SR^a$, $-S(=O)R^a$,
 $-S(=O)_2R^a$, $-S(=O)_2NR^aR^a$, $-S(=O)_2N(R^a)C(=O)R^a$, $-S(=O)_2N(R^a)C(=O)OR^a$,
 $-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$, $-N(R^a)C(=O)OR^a$,
 $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$,
25 $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$ and $-NR^aC_{2-6}alkOR^a$, wherein the
available carbon atoms of the ring are additionally substituted by 0, 1 or 2 oxo or
thioxo groups.

In another embodiment, in conjunction with the above and below
embodiments, R^1 is a direct-bonded unsaturated 6-membered monocyclic ring
30 containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more
than one O or S atom, substituted by 0, 1, 2 or 3 substituents independently

- 16 -

selected from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a,
 -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a,
 -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a,
 -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a,
 5 -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a, -N(R^a)C(=O)OR^a,
 -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a,
 -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a.

In another embodiment, in conjunction with the above and below
 embodiments, R¹ is phenyl, pyridyl or pyrimidinyl, all of which are substituted by
 10 0, 1, 2 or 3 substituents independently selected from halo, C₁₋₆alk, C₁₋₄haloalk,
 cyano, nitro, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a,
 -OC(=O)R^a, -OC(=O)NR^aR^a, -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a,
 -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a, -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a,
 -S(=O)₂N(R^a)C(=O)OR^a, -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a,
 15 -N(R^a)C(=O)OR^a, -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a,
 -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a.

In another embodiment, in conjunction with the above and below
 embodiments, R¹ is phenyl substituted by 0, 1, 2 or 3 substituents independently
 selected from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a,
 20 -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a,
 -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a,
 -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a,
 -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a, -N(R^a)C(=O)OR^a,
 -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a,
 25 -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a.

In another embodiment, in conjunction with the above and below
 embodiments, R¹ is phenyl, pyridyl or pyrimidinyl, all of which are substituted by
 1, 2 or 3 substituents independently selected from halo, C₁₋₆alk, and C₁₋₄haloalk.

In another embodiment, in conjunction with the above and below
 30 embodiments, R¹ is phenyl which is substituted by 1, 2 or 3 substituents
 independently selected from halo, C₁₋₆alk, and C₁₋₄haloalk.

- 17 -

In another embodiment, in conjunction with the above and below embodiments, R^2 is H.

In another embodiment, in conjunction with the above and below embodiments, R^3 is selected from H and halo.

5 In another embodiment, in conjunction with the above and below embodiments, R^4 is selected from H and halo.

In another embodiment, in conjunction with the above and below embodiments, R^3 and R^4 are both H.

10 In another embodiment, in conjunction with the above and below embodiments, R^5 is, independently, in each instance, H, halo, C_{1-6} alk, and C_{1-4} haloalk.

In another embodiment, in conjunction with the above and below embodiments, one R^5 is H and the other R^5 is C_{1-6} alk.

15 In another embodiment, in conjunction with the above and below embodiments, one R^5 is H and the other R^5 is methyl.

In another embodiment, in conjunction with the above and below embodiments, one R^5 is H and the other R^5 is (R)-methyl.

In another embodiment, in conjunction with the above and below embodiments, one R^5 is H and the other R^5 is (S)-methyl.

20 In another embodiment, in conjunction with the above and below embodiments, R^6 is NHR^9 .

In another embodiment, in conjunction with the above and below embodiments, R^7 is cyano.

25 In another embodiment, in conjunction with the above and below embodiments, R^7 and R^8 together form a $-C=N-$ bridge wherein the carbon atom is substituted by H, halo, cyano, or a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the
30 ring is substituted by 0, 1, 2, 3 or 4 substituents selected from halo, C_{1-6} alk, C_{1-4} haloalk, cyano, nitro, $-C(=O)R^a$, $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$,

- 18 -

-OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a, -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a,
 -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a, -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a,
 -S(=O)₂N(R^a)C(=O)OR^a, -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a,
 -N(R^a)C(=O)OR^a, -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a,
 5 -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a.

In another embodiment, in conjunction with the above and below
 embodiments, R⁷ and R⁹ together form a -N=C- bridge wherein the carbon atom is
 substituted by H, halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, OR^a, NR^aR^a, -C(=O)R^a,
 -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -S(=O)R^a, -S(=O)₂R^a,
 10 -S(=O)₂NR^aR^a.

In another embodiment, in conjunction with the above and below
 embodiments, R⁷ and R⁹ together form a -N=C- bridge wherein the carbon atom is
 substituted by H or halo.

In another embodiment, in conjunction with the above and below
 15 embodiments, R¹¹ is selected from H, halo, C₁₋₆alk, C₁₋₄haloalk and cyano.

In another embodiment, in conjunction with the above and below
 embodiments, R¹¹ is selected from H, halo and C₁₋₆alk.

Another aspect of the invention relates to a method of treating PI3K-
 mediated conditions or disorders.

20 In certain embodiments, the PI3K-mediated condition or disorder is
 selected from rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic
 arthritis, psoriasis, inflammatory diseases, and autoimmune diseases. In other
 embodiments, the PI3K- mediated condition or disorder is selected from
 cardiovascular diseases, atherosclerosis, hypertension, deep venous thrombosis,
 25 stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary
 embolism, thrombolytic diseases, acute arterial ischemia, peripheral thrombotic
 occlusions, and coronary artery disease. In still other embodiments, the PI3K-
 mediated condition or disorder is selected from cancer, colon cancer,
 glioblastoma, endometrial carcinoma, hepatocellular cancer, lung cancer,
 30 melanoma, renal cell carcinoma, thyroid carcinoma, cell lymphoma,
 lymphoproliferative disorders, small cell lung cancer, squamous cell lung

- 19 -

carcinoma, glioma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, and leukemia. In yet another embodiment, the PI3K- mediated condition or disorder is selected from type II diabetes. In still other embodiments, the PI3K- mediated condition or disorder is selected from respiratory diseases, bronchitis, 5 asthma, and chronic obstructive pulmonary disease. In certain embodiments, the subject is a human.

Another aspect of the invention relates to the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases or autoimmune diseases comprising the step of 10 administering a compound according to any of the above embodiments.

Another aspect of the invention relates to the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases and autoimmune diseases, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, skin 15 complaints with inflammatory components, chronic inflammatory conditions, autoimmune diseases, systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions and hypersensitivity, 20 comprising the step of administering a compound according to any of the above or below embodiments.

Another aspect of the invention relates to the treatment of cancers that are mediated, dependent on or associated with p110 δ activity, comprising the step of administering a compound according to any of the above or below embodiments.

25 Another aspect of the invention relates to the treatment of cancers are selected from acute myeloid leukaemia, myelo-dysplastic syndrome, myelo-proliferative diseases, chronic myeloid leukaemia, T-cell acute lymphoblastic leukaemia, B-cell acute lymphoblastic leukaemia, non-hodgkins lymphoma, B-cell lymphoma, solid tumors and breast cancer, comprising the step of 30 administering a compound according to any of the above or below embodiments.

- 20 -

Another aspect of the invention relates to a pharmaceutical composition comprising a compound according to any of the above embodiments and a pharmaceutically-acceptable diluent or carrier.


Another aspect of the invention relates to the use of a compound according to any of the above embodiments as a medicament.

Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases.

The compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diastereomers.

Unless otherwise specified, the following definitions apply to terms found in the specification and claims:

“C_{α-β}alk” means an alk group comprising a minimum of α and a maximum of β carbon atoms in a branched, cyclical or linear relationship or any combination of the three, wherein α and β represent integers. The alk groups described in this section may also contain one or two double or triple bonds. Examples of C₁₋₆alk include, but are not limited to the following:



"Benzo group", alone or in combination, means the divalent radical C₄H₄=, one representation of which is -CH=CH-CH=CH-, that when vicinally attached to another ring forms a benzene-like ring--for example tetrahydronaphthylene, indole and the like.



The terms “oxo” and “thioxo” represent the groups =O (as in carbonyl) and =S (as in thiocarbonyl), respectively.

“Halo” or “halogen” means a halogen atoms selected from F, Cl, Br and I.

- 21 -

“C_V-haloalk” means an alk group, as described above, wherein any number--at least one--of the hydrogen atoms attached to the alk chain are replaced by F, Cl, Br or I.

“Heterocycle” means a ring comprising at least one carbon atom and at least one other atom selected from N, O and S. Examples of heterocycles that may be found in the claims include, but are not limited to, the following:



- 22 -

“Available nitrogen atoms” are those nitrogen atoms that are part of a heterocycle and are joined by two single bonds (e.g. piperidine), leaving an external bond available for substitution by, for example, H or CH₃.

"Pharmaceutically-acceptable salt" means a salt prepared by conventional means, and are well known by those skilled in the art. The "pharmacologically acceptable salts" include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like. When compounds of the invention include an acidic function such as a carboxy group, then suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like. For additional examples of "pharmacologically acceptable salts," *see infra* and Berge et al., J. Pharm. Sci. 66:1 (1977).

“Saturated, partially saturated or unsaturated” includes substituents saturated with hydrogens, substituents completely unsaturated with hydrogens and substituents partially saturated with hydrogens.

"Leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.

"Protecting group" generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralk, substituted aralk, cycloalkenylalk and substituted cycloalkenyl alk, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like.

- 23 -

Examples of aralk include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alk, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like. Examples of cycloalkenylalk or substituted cycloalkenylalk radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, trifluoroacetyl, trichloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralk group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, 1,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalk rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl. Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralk groups. Alk groups are also suitable groups for protecting hydroxy and mercapto groups, such as tert-butyl.

Silyl protecting groups are silicon atoms optionally substituted by one or more alk, aryl and aralk groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a N,N,O-trisilyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or


- 24 -

ammonium fluoride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butyl-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with
5 imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol
10 chemistry.

Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl
15 group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be
20 neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.

It should be noted that compounds of the invention may contain groups that may
25 exist in tautomeric forms, such as cyclic and acyclic amidine and guanidine groups, heteroatom substituted heteroaryl groups ($Y' = O, S, NR$), and the like, which are illustrated in the following examples:

- 25 -



and though one form is named, described, displayed and/or claimed herein, all the tautomeric forms are intended to be inherently included in such name, description, display and/or claim.

- 5 Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient. The suitability and techniques involved in making and using
- 10 prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alk (for example, methyl, ethyl), cycloalk (for example, cyclohexyl), aralk (for example, benzyl, p-methoxybenzyl), and alkcarbonyloxyalk (for example, pivaloyloxymethyl).
- 15 Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bundgaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-
- 20 acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)).

- 26 -

Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.

The specification and claims contain listing of species using the language
5 “selected from . . . and . . .” and “is . . . or . . .” (sometimes referred to as Markush groups). When this language is used in this application, unless otherwise stated it is meant to include the group as a whole, or any single members thereof, or any subgroups thereof. The use of this language is merely for shorthand purposes and is not meant in any way to limit the removal of individual elements or subgroups
10 as needed.

The present invention also includes isotopically-labelled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that
15 can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{16}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , and ^{36}Cl .

Compounds of the present invention that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this
20 invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as ^3H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detection. Further, substitution with heavier isotopes
25 such as deuterium, i.e., ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of this invention can generally be prepared by substituting a readily available isotopically labeled reagent for a non-isotopically
30 labeled reagent.

- 27 -

Experimental

The following abbreviations are used:

	aq. -	aqueous
	BINAP -	2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
5	concd -	concentrated
	DCM -	dichloromethane
	DIAD -	diisopropyl azodicarboxylate
	DMF -	N,N-dimethylformamide
	Et ₂ O -	diethyl ether
10	EtOAc -	ethyl acetate
	EtOH -	ethyl alcohol
	h -	hour(s)
	min -	minutes
	MeOH -	methyl alcohol
15	MsCl -	methanesulfonyl chloride
	rt -	room temperature
	satd -	saturated
	THF -	tetrahydrofuran

General


- 20 Reagents and solvents used below can be obtained from commercial sources.
- ¹H-NMR spectra were recorded on a Bruker 400 MHz and 500 MHz NMR spectrometers. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet), coupling constant(s) in Hertz (Hz) and number of protons. Mass spectrometry results are
- 25 reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses Electrospray ionization (ESI) mass spectrometry analysis was conducted on a Agilent 1100 series LC/MSD electrospray mass spectrometer. All compounds could be analyzed in the positive ESI mode using
- 30 acetonitrile:water with 0.1% formic acid as the delivery solvent. Reverse phase analytical HPLC was carried out using a Agilent 1200 series on Agilent Eclipse XDB-C18 5 μm column (4.6 x 150 mm) as the stationary phase and eluting with

- 28 -

acetonitrile:water with 0.1% TFA. Reverse phase Semi-Prep HPLC was carried out using a Agilent 1100 Series on a Phenomenex Gemini™ 10 µm C18 column (250 x 21.20 mm) as the stationary phase and eluting with acetonitrile:H₂O with 0.1% TFA.


5 Example 1

1-(2-Bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethanol



To a solution of 2-bromo-6-chlorothieno[2,3-b]pyridine-5-carbaldehyde (2.4 g, 8.7 mmol) (Meth-Cohn, O. Narine B. *Tetrahedron Lett.*, **1978**, 2045) in THF (50 mL) at -20 °C was added methylmagnesiumchloride (3.04 mL of 3N in THF, 9.1 mmol) dropwise. The reaction was stirred at -20°C for 45 minutes and then quenched with 25 mL NH₄Cl (sat) and 25 mL of water. The reaction was diluted with ether and the layers were separated. The organic layer was washed with brine and concentrated. Purification by column chromatography afforded 1-(2-bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethanol. LC/MS (M+1, found = 293.8). ¹H NMR (400 MHz, CDCl₃) δ 8.21 (s, 1H), 7.30 (s, 1H), 5.32 (qd, *J* = 6.3, 2.7 Hz, 1H), 2.19 (br s, 1H), 1.55 (d, *J* = 6.3 Hz, 3H) ppm.

2-(1-(2-Bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione




To a round-bottomed flask containing 1-(2-bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethanol (2.0 g, 6.8 mmol), phthalimide (1.2 g, 8.2 mmol, 1.2 eq), and triphenylphosphine (2.15 g, 8.2 mmol) was added THF (45 mL). The solution was cooled to 0 °C and diisopropylazodicarboxylate (DIAD, 1.6 mL, 8.2 mmol, 1.2 eq) was added dropwise. The reaction was allowed to warm to room temperature. After 1 h, the reaction was judged to be complete by LC/MS. The solvent was

- 29 -


removed in vacuo and the residue was redissolved in ether and washed with water. The water layer was back extracted with ether. The combined ether layers were washed with brine and dried over MgSO_4 , filtered, and concentrated. The crude product was purified by column chromatography using 15% EA in hexanes to afford 2-(1-(2-bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione. LC/MS ($M+1$, found = 422.8). ^1H NMR (400 MHz, CDCl_3) δ 8.40 (s, 1H), 7.82 (m, 2H), 7.72 (m, 2H), 5.92 (q, $J = 7.0$ Hz, 1H), 1.92 (d, $J = 7.0$ Hz, 3H) ppm.

2-(1-(6-Chlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione:




In a hydrogenation apparatus, 2-(1-(2-bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione (800 mg, 1.9 mmol) and 5% palladium on carbon (151 mg) were combined. The reaction vessel was purged with nitrogen and 60 mL ethyl acetate, 15 mL ethanol, and 15 drops of concentrated HCl were added. The reaction vessel was pressurized with hydrogen gas to 50 psi. After 4 days, the apparatus was purged with nitrogen and the contents were filtered through celite. The CeliteTM pad was washed with ethyl acetate to afford an orange solution. The solvent was removed on the rotovap and redissolved in dichloromethane. Silica gel (3.2 g) was added to the dichloromethane solution and the solvent was removed on the rotovap. The silica gel was transferred to the head of a chromatography column and eluted with 15% ethyl acetate in hexanes to afford 2-(1-(6-chlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione and recovered 2-(1-(2-bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione. LC/MS ($M+1$, found = 343.0). ^1H NMR (400 MHz, CDCl_3) δ 8.52 (s, 1H), 7.82 (m, 2H), 7.72 (m, 2H), 7.54 (d, $J = 5.9$ Hz, 1H), 7.32 (d, $J = 5.9$ Hz, 1H), 5.95 (q, $J = 7.0$ Hz, 1H), 1.95 (d, $J = 7.0$ Hz, 3H) ppm.

- 30 -

2-(1-(6-(Pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione:

A mixture of 2-(1-(6-chlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione (300 mg, 0.875 mmol), 2-(tributylstannyl)pyridine (340 μ L, 1.05 mmol, 1.2 eq) and tetrakis(triphenylphosphine)palladium(0) (101 mg, 0.0875 mmol, 0.1 eq) was dissolved in 10 mL of dioxane under nitrogen. The reaction was heated to 100 °C for 2 days, cooled to rt and concentrated *in vacuo*. Purification by column chromatography using ethyl acetate / hexanes afforded 2-(1-(6-(pyridin-2-yl)-thieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione. LC/MS (M+1, found = 386.0). ¹H NMR (400 MHz, CDCl₃) δ 8.69 (s, 1H), 8.66 (ddd, J = 4.9, 1.6, 0.8 Hz, 1H), 7.76 (td, J = 7.8, 1.8 Hz, 1H), 7.73-7.62, series of m, 5H), 7.57 (d, J = 5.9 Hz, 1H), 7.36 (d, J = 5.9 Hz, 1H), 7.31 (ddd, J = 7.2, 4.7, 1.4 Hz, 1H), 6.33 (q, J = 7.2 Hz, 1H), 1.99 (d, J = 7.2 Hz, 3H) ppm.

1-(6-(Pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethanamine

15


2-(1-(6-(Pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione (220 mg, 0.57 mmol) was slurried in ethanol (5 mL). To this slurry was added hydrazine hydrate (500 μ L, 10.3 mmol, 18 eq). The reaction was heated to 60 °C for 2 h, then cooled to rt and filtered. The filtrate was concentrated and redissolved in ethyl acetate and water. The layers were separated and the organic layer was washed with brine, dried over MgSO₄, filtered, and

20

- 31 -

concentrated *in vacuo* to afford 1-(6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)-ethanamine (134 mg, 91.9% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.69 (ddd, J = 4.7, 1.6, 0.8 Hz, 1H), 8.39 (s, 1H), 7.87 (m, 2H), 7.57 (d, J = 5.9 Hz, 1H), 7.34 (ddd, J = 6.8, 5.1, 2.0, 1H), 7.31 (d, J = 5.9 Hz, 1H), 4.63 (q, J = 6.7 Hz, 1H), 1.44 (d, J = 6.7 Hz, 3H) ppm.

N-(1-(6-(Pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)-9H-purin-6-amine:




To a reaction flask containing 1-(6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethanamine (134 mg, 0.525 mmol), 6-chloropurine (97 mg, 0.63 mmol, 1.2 eq) and diisopropylethylamine (137 μL, 0.79 mmol, 1.5 eq) was added 5 mL of n-butanol. The reaction was heated to 110 °C for 24 h, then cooled to rt and concentrated *in vacuo*. The residue was dissolved in ethyl acetate (~ 50 mL) with heat and sonication, then washed with 5 mL water and 5 mL brine. The organic layer was dried over MgSO₄, filtered, and concentrated. Purification by column chromatography using 0-80% gradient of (90:9:1 DCM:MeOH:NH₄OH) in dichloromethane afforded racemic N-(1-(6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)-9H-purin-6-amine. The room temperature NMR spectrum in CDCl₃ exists as a roughly 3:1 mixture of isomers. ¹H NMR (400 MHz, CDCl₃) δ 8.80 (br d, J = 4.3 Hz, 0.75 H), 8.73 (br d, J = 3.1 Hz, 0.25 H), 8.55 (s, 0.25 H), 8.36-8.26 (series of m, 1.75 H), 8.15-8.03 (series of m, 1.5 H), 7.93 (br s, 0.75 H), 7.88 (m, 1.4 H), 7.56 (m, 0.5 H), 7.55 (d, J = 5.9 Hz, 0.75 H), 7.37 (dd, J = 6.6, 5.1 Hz, 0.75 H), 7.26 (d, J = 5.9 Hz, 0.75 H), 7.20 (d, J = 5.9 Hz, 0.25 H), 6.65 (m, 0.25 H), 6.35 (m, 0.25 H), 6.15 (br s, 0.75 H), 1.55 (d, J = 7.0 Hz, 2.25 H), 1.35 (d, J = 6.3 Hz, 0.75 H) ppm. LC/MS (M+1, found = 374.0). Chiral SFC separation of the racemate afforded the individual enantiomers, (S)-N-(1-(6-(pyridin-2-

- 32 -

yl)thieno[2,3-b]pyridin-5-yl)ethyl)-9H-purin-6-amine and (*R*)-N-(1-(6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)-9H-purin-6-amine.


Example 2

1-(2-Bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethanone:



A 2.2 g (7.5 mmol) portion of 1-(2-bromo-6-chlorothieno[2,3-b]pyridin-5-yl)-ethanol was dissolved in toluene and treated with manganese dioxide (6.5 g, 75 mmol, 10 eq). The mixture was heated to 90 °C overnight, then cooled rt and filtered through Celite™. The filter cake was rinsed with toluene and concentrated to afford crude material. The residue was purified by column chromatography using ethyl acetate in hexanes to afford 1-(2-bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethanone. LC/MS ($M+1$, found = 291.9). ^1H NMR (400 MHz, CDCl_3) δ 8.17 (s, 1H), 7.36 (s, 1H), 2.75 (s, 3H) ppm.

(*R*)-1-(2-Bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethanol:




In 30 mL of THF was dissolved (+)-dip-chloride(tm) (3.3 g, 10.2 mmol, 2.2 eq) and the resulting solution was cooled to -55 °C. To this solution was added 1-(2-bromo-6-chlorothieno[2,3-b]pyridin-5-yl)ethanone in 10 mL of THF via cannula, followed by a rinse with 10 mL of THF. The reaction was allowed to warm to RT slowly overnight and then quenched with 5 mL of acetone and 50% sat. Na_2CO_3 . After stirring for 1 h, the reaction was diluted with ethyl acetate (100 mL) and transferred to a separatory funnel. The organic layer was washed with 2 x 50 mL of 50% sat. Na_2CO_3 , 2 x 50 mL of water, and 2 x 50 mL of brine. The organic layer was dried over MgSO_4 , filtered, and concentrated. Purification of the crude was achieved by slurrying in 20 mL water and 50 mL hexanes. The resulting solid was filtered and dried overnight to afford a pure white powder,

- 33 -


(R)-1-(2-bromo-6-chlorothiено[2,3-b]pyridin-5-yl)ethanol. Chiral HPLC (Chiralcel-AD, 30% isopropanol / hexanes) = 92% ee. ^1H NMR (400 MHz, CDCl_3) δ 8.22 (s, 1H), 7.31 (s, 1H), 5.32 (dq, $J = 5.9, 3.5$ Hz, 1H), 2.17 (d, $J = 3.5$ Hz, 1H), 1.56 (d, $J = 6.3$ Hz, 3H) ppm.

5 **(S)-2-(1-(2-Bromo-6-chlorothiено[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione:**



(S)-2-(1-(2-Bromo-6-chlorothiено[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione was obtained from (R)-1-(2-bromo-6-chlorothiено[2,3-b]pyridin-5-yl)ethanol in the manner described for racemic 2-(1-(2-bromo-6-chlorothiено[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione. LC/MS ($M+1$, found = 423.0). ^1H NMR (400 MHz, CDCl_3) δ 8.40 (s, 1H), 7.82 (m, 2H), 7.72 (m, 2H), 5.92 (q, $J = 7.0$ Hz, 1H), 1.92 (d, $J = 7.0$ Hz, 3H) ppm.

(S)-2-(1-(6-Chlorothiено[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione:




(S)-2-(1-(6-Chlorothiено[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione was obtained from (S)-2-(1-(2-bromo-6-chlorothiено[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione in the manner described for racemic 2-(1-(6-chlorothiено[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione. LC/MS ($M+1$, found = 343.0). ^1H NMR (400 MHz, CDCl_3) δ 8.52 (s, 1H), 7.82 (m, 2H), 7.72 (m, 2H), 7.54 (d, $J =$

- 34 -

5.9 Hz, 1H), 7.32 (d, $J = 5.9$ Hz, 1H), 5.95 (q, $J = 7.0$ Hz, 1H), 1.95 (d, $J = 7.0$ Hz, 3H) ppm.

(S)-1-(6-(3-Fluorophenyl)thieno[2,3-b]pyridin-5-yl)ethanamine:




- 5 In a 25 mL round-bottomed reaction flask was combined tetrakis(triphenylphosphine)palladium(0) (25 mg, 22 μ mol), 3-fluorophenylboronic acid (67 mg, 481 μ mol), sodium carbonate (232 mg, 2188 μ mol), and (S)-2-(1-(6-chlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione (150 mg, 438 μ mol). The reaction flask was flushed with nitrogen before the addition of 4 mL of 3:1
- 10 acetonitrile:water. The reaction was heated to 90 °C for three days, after which time the reaction was not complete. The reaction was worked up by removing the solvent and repartitioning between 10 mL dichloromethane and 10 mL water. The dichloromethane layer was separated and extracted with 10 mL of 50% sat. Na_2CO_3 . The pH of the combined aq layers were adjusted to 1 using 20 mL of
- 15 1N HCl, forming a white solid. Dichloromethane was added to dissolve the solid and the organic layer was separated off. The aq. layer was extracted twice with 10 mL of dichloromethane and the combined organics were dried over MgSO_4 , filtered, and concentrated. The crude material was dissolved in 3 mL MeCN and 1 mL water. To this was added 115 mg Na_2CO_3 , 35 mg 3-fluorophenylboronic acid, and 13 mg tetrakis triphenylphosphine. The reaction was
- 20 heated to 90 °C overnight, then cooled to room temperature and worked up as above. Subjected to column chromatography (DCM:MeOH). To afford 2-(((S)-1-(6-(3-fluorophenyl)thieno[2,3-b]pyridin-5-yl)ethyl)carbamoyl)benzoic acid. The product was then dissolved in 3 mL ethanol and treated with

- 35 -

concentrated HCl (118 μ L, 1427 μ mol). The reaction was heated to 80 $^{\circ}$ C for 2 days, after which time an additional charge of HCl (118 μ L, 1427 μ mol) was added and heated at 80 $^{\circ}$ C for 1 day. The reaction was cooled to rt and diluted with 6 mL of water. The pH of the solution was adjusted to 10 using 1N NaOH. The reaction was extracted with dichloromethane and the organic layer was dried over Na₂SO₄, filtered and concentrated. The residue was treated with 2 mL of ethanol, forming a suspension. To this suspension was added hydrazine monohydrate (71 μ L, 1427 μ mol). After stirring at 60 $^{\circ}$ C for 2 h, the reaction was cooled to rt and diluted with ethyl acetate, filtered, and concentrated. The residue was dissolved in 20 mL of ethyl acetate and washed with 1 x 3 mL of water, and 1 x 3 mL of brine, dried over MgSO₄, filtered, concentrated to afford crude (1S)-1-(6-(3-fluorophenyl)thieno[2,3-b]pyridin-5-yl)ethanamine. LC/MS (M+1, found = 273.0).

N-((S)-1-(6-(3-Fluorophenyl)thieno[2,3-b]pyridin-5-yl)ethyl)-9H-purin-6-amine:




In a reaction flask was combined (1S)-1-(6-(3-fluorophenyl)thieno[2,3-b]pyridin-5-yl)ethanamine (39 mg, 143 μ mol), 6-chloropurine (24 mg, 158 μ mol), Hunig's Base (38 μ L, 215 μ mol) and n-butanol (1.5 mL). The solution was heated to 110 $^{\circ}$ C. After 24 h, the solvent was removed and the residue purified by column chromatography using a 0-70% gradient of (90:9:1 CH₂Cl₂:MeOH:NH₄OH) in CH₂Cl₂ to afford N-((S)-1-(6-(3-fluorophenyl)thieno[2,3-b]pyridin-5-yl)ethyl)-9H-purin-6-amine. ¹H NMR (400 MHz, DMSO-d₆) δ 12.90 (br s, 1H), 8.51 (br s, 1H), 8.34 (br s, 1H), 8.10 (m, 2H), 7.88 (d, J = 5.9 Hz, 1H), 7.59 (m, 3H), 7.45

- 36 -

(d, $J = 5.9$ Hz, 1H), 7.30 (br t, $J = 6.3$ Hz, 1H), 5.60 (br s, 1H), 1.44 (br d, $J = 5.1$ Hz, 3H) ppm. LC/MS ($M+1$, found = 391.1).


Example 3

(E)-1-(5-Chlorothiophen-2-yl)ethanone oxime:



Combined 1-(5-chlorothiophen-2-yl)ethanone (100g, 622 mmol), hydroxylamine hydrochloride (47.6 g, 685 mmol, 1.1 eq) and sodium acetate (56.2 g, 685 mmol, 1.1 eq) in 1 L of ethanol and 300 mL of water. The reaction was heated to reflux. After 3 h, the reaction was cooled to rt and concentrated. The residue was slurried in 500 mL of water overnight, filtered and dried to afford the crude solid. Purified by extraction of the solid with hot dichloromethane, cooling to rt and filtering to remove unreacted starting material. The solid was slurried in hot dichloromethane several times to extract the solid enriched in the first eluting (E-oxime) compound (100% DCM) after concentration. The highly crystalline material was purified by column chromatography using 100% dichloromethane to afford (E)-1-(5-chlorothiophen-2-yl)ethanone oxime. NMR (400 MHz, DMSO- d_6) δ 11.31 (s, 1H), 7.21 (d, $J = 3.9$ Hz, 1H), 7.07 (d, $J = 3.9$ Hz, 1H), 2.12 (s, 3H) ppm.

N-(5-Chlorothiophen-2-yl)acetamide:




(E)-1-(5-Chlorothiophen-2-yl)ethanone oxime (10.7 g, 60.9 mmol) was dissolved in 180 mL of acetone. To this solution was added 4-methylbenzene-1-sulfonyl chloride (11.61 g, 60.9 mmol, 1 eq) and sodium hydroxide (2.437 g, 60.9 mmol, 1 eq) in 61 mL of water at 0 °C. The reaction was allowed to warm to rt over 1 h. After 3 h, the reaction was warmed to 60 °C for 1.5 h. After cooling to rt, the solvent was removed *in vacuo*. The residue was dissolved in ethyl acetate (300 mL) and washed with water, sat. NaHCO_3 , and brine. The organic layer was

- 37 -


dried over MgSO_4 , filtered and concentrated. The residue was slurried in 60 mL of hot dichloromethane, cooled to 0 °C and filtered to afford N-(5-chlorothiophen-2-yl)acetamide as a grey powder. NMR (400 MHz, DMSO-d_6) δ 11.34 (s, 1H), 6.83 (d, $J = 3.9$, 1H), 6.42 (d, $J = 3.9$ Hz, 1H), 2.05 (s, 3H) ppm.

5 **2,6-Dichlorothieno[2,3-b]pyridine-5-carbaldehyde:**



To phosphoryl trichloride (32.8 mL, 359 mmol) at 0 °C was added N,N-dimethylformamide (11.90 mL, 154 mmol) dropwise. After stirring for 20 min, the solution was warmed to rt for 30 min and N-(5-chlorothiophen-2-yl)acetamide (9 g, 51.2 mmol) was added as a solid. The mixture was heated to 75 °C for 4 h, cooled to rt, and poured into 500 g of ice water. The quenched reaction was stirred in an ice bath for 30 minutes and filtered. The solid was dried under vacuum overnight to afford the crude solid. The crude solid was extracted with boiling ethyl acetate and decanted to separate it from an insoluble tar. The organic layer was concentrated and the residue was recrystallized from ethyl acetate to afford the pure product. The mother liquor was passed through a plug of silica gel and recrystallized from ethyl acetate to afford additional product, 2,6-dichlorothieno[2,3-b]pyridine-5-carbaldehyde. ^1H NMR (400 MHz, CDCl_3) δ 10.50 (s, 1H), 8.46 (s, 1H), 7.25 (s, 1H) ppm.

20 **1-(2,6-Dichlorothieno[2,3-b]pyridin-5-yl)ethanol:**




To a reaction flask containing 2,6-dichlorothieno[2,3-b]pyridine-5-carbaldehyde (5.1 g, 21.97 mmol) in 300 mL of THF at -20 °C was added methylmagnesium chloride, 3.0M solution in tetrahydrofuran (7.69 mL, 23.07 mmol) dropwise. After 1 h, an additional charge of 0.7 mL of MeMgCl was added. After 15 min,

- 38 -


the reaction was quenched by the addition of 50 mL sat. NH_4Cl and 50 mL water. After warming to rt, ethyl acetate was added and the organic layer was separated and washed with water and brine. The organic layer was dried over MgSO_4 , filtered, and concentrated to afford 1-(2,6-dichlorothieno[2,3-b]pyridin-5-yl)-ethanol. ^1H NMR (400 MHz, CDCl_3) δ 8.19 (d, $J = 0.8$ Hz, 1H), 7.14 (s, 1H), 5.32 (qdd, $J = 6.3, 3.5, 0.8$ Hz, 1H), 2.07 ($J = 3.5$ Hz, 1H), 1.56 (d, $J = 6.6$ Hz, 3H) ppm.

1-(2,6-Dichlorothieno[2,3-b]pyridin-5-yl)ethanone:



To a solution of 1-(2,6-dichlorothieno[2,3-b]pyridin-5-yl)ethanol (5 g, 20.15 mmol) in 200 mL of anhydrous toluene was added MnO_2 (14 g, 161 mmol). The reaction was heated to reflux overnight, cooled to rt, filtered through CeliteTM and rinsed with ethyl acetate. Concentration and purification by column chromatography afforded 1-(2,6-dichlorothieno[2,3-b]pyridin-5-yl)ethanone. ^1H NMR (400 MHz, CDCl_3) δ 8.15 (s, 1H), 7.19 (s, 1H), 2.75 (s, 3H) ppm.

(R)-1-(2,6-Dichlorothieno[2,3-b]pyridin-5-yl)ethanol:




1-(2,6-Dichlorothieno[2,3-b]pyridin-5-yl)ethanone (3.6 g, 14.63 mmol) was dissolved in THF (100 mL) and cooled to -55°C in a dry ice / MeCN bath. To this solution was added a solution of (+)-dip-chloride(tm) (10.32 g, 32.2 mmol) in THF dropwise. The reaction was allowed to warm slowly to rt overnight and quenched by addition of 10 mL of acetone and 50 mL of 50% sat. Na_2CO_3 . The reaction was stirred for 1 h and diluted with 400 mL of ethyl acetate. The organic layer was washed with 2 x 100 mL of 50% sat Na_2CO_3 , 2 x 100 mL of water, and 2 x 100 mL of brine. The reaction was dried over MgSO_4 , filtered and concentrated. The residue was slurried in 100 mL water / 200 mL hexanes

- 39 -


for 3 h to form white ppt that was filtered and dried to afford (R)-1-(2,6-dichloro-thieno[2,3-b]pyridin-5-yl)ethanol. Enantiomeric excess as determined by chiral HPLC was found to be = 99%. ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, J = 0.8 Hz, 1H), 7.14 (s, 1H), 5.32 (qdd, J = 6.3, 3.5, 0.8 Hz, 1H), 2.07 (J = 3.5 Hz, 1H), 1.56 (d, J = 6.6 Hz, 3H) ppm.

(S)-2-(1-(2,6-Dichlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione:



In a reaction flask was combined phthalimide (1.530 g, 10.40 mmol), triphenylphosphine (2.73 g, 10.40 mmol), (R)-1-(2,6-dichlorothieno[2,3-b]pyridin-5-yl)ethanol (2.15 g, 8.66 mmol) and tetrahydrofuran (57.8 mL). The reaction was cooled to 0 °C and diisopropyl azodicarboxylate (2.043 mL, 10.40 mmol) was added dropwise. The reaction was removed from the ice bath and allowed to warm to rt and stir overnight. The reaction was diluted with ethyl acetate and washed with NaHCO₃ and brine. The organic layer was dried over MgSO₄, filtered and concentrated. Purification using 5-10% ethyl acetate in hexanes afforded (S)-2-(1-(2,6-dichlorothieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione. ¹H NMR (400 MHz, CDCl₃) δ 8.37 (s, 1H), 7.82 (m, 2H), 7.73 *m, 2H), 7.18 (s, 1H), 5.90 (q, 7.3 Hz, 1H), 1.90 (d, J = 7.2 Hz, 3H) ppm.

(S)-2-(1-(6-Chloro-2-methylthieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione:




- 40 -

In a microwave vessel was combined potassium carbonate (183 mg, 1.325 mmol), trimethylboroxine (0.018 mL, 0.133 mmol), (S)-2-(1-(2,6-dichlorothieno[2,3-b]-pyridin-5-yl)ethyl)isoindoline-1,3-dione (100 mg, 0.265 mmol), tetrakis triphenylphosphine palladium(0) (45.9 mg, 0.040 mmol), and 2.5 mL of DMF. The


5 reaction was subjected to microwave heating for 30 min at 120 °C. After cooling, the reaction was dissolved in ethyl acetate and washed with water and brine, dried over MgSO₄, filtered and concentrated. Purification by column chromatography to afforded the impure (S)-2-(1-(6-chloro-2-methylthieno[2,3-b]-pyridin-5-yl)ethyl)isoindoline-1,3-dione (30 mg, 0.084 mmol, 31.7 % yield). ¹H NMR (400 MHz, CDCl₃) δ 8.31 (s, 1H), 7.81 (m, 2H), 7.71 (m, 2H), 6.95 (q, 1.2 Hz, 1H), 5.91 (q, J = 6.8 Hz, 1H), 2.60 (d, J = 1.2 Hz, 3H), 1.91 (d, J = 7.2 Hz, 3H) ppm.

(S)-2-(1-(2-Methyl-6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione:




15 In a reaction vessel was combined 2-(1,1,1-tributylstannyl)pyridine (0.124 ml, 0.370 mmol), tetrakis triphenylphosphine(0) (35.6 mg, 0.031 mmol), (S)-2-(1-(6-chloro-2-methylthieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione (110 mg, 0.308 mmol) in dioxane (3 mL). The reaction was heated to 100 °C for 2 d, cooled to rt, and diluted with ethyl acetate. The organic phase was washed with NaHCO₃ and brine, dried over MgSO₄, filtered and concentrated. Purification by column chromatography afforded (S)-2-(1-(2-methyl-6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)isoindoline-1,3-dione. ¹H NMR (400 MHz, CDCl₃) δ 8.64 (ddd, J = 4.7, 1.8, 0.8 Hz, 1H), 7.72 (td J = 7.8, 2.0 Hz, 1H), 7.67 (m, 3H), 7.62 (m, 2H), 7.29 (ddd, J = 7.4, 4.9, 1.6 Hz, 1H), 6.98 (q, J = 1.4 Hz, 1H), 6.30 (q, J = 7.0 Hz, 1H), 2.60 (d, J = 1.2 Hz, 3H), 1.97 (d, J = 7.2 Hz, 3H) ppm.

- 41 -

(S)-1-(2-Methyl-6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethanamine:

Slurried (S)-2-(1-(2-methyl-6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)iso-
indoline-1,3-dione (60 mg, 0.150 mmol) in 3.5 mL of ethanol was warmed to 60
5 °C and hydrazine monohydrate (73.0 µL, 1.502 mmol) was added. The reaction
was stirred at 60 °C for 2 h, cooled to RT and diluted with ethyl acetate. The
reaction was filtered and concentrated. The resulting residue was redissolved in
ethyl acetate and washed with water and brine, dried over MgSO₄, filtered and
concentrated to afford crude (S)-1-(2-methyl-6-(pyridin-2-yl)thieno[2,3-b]pyridin-
10 5-yl)ethanamine. ¹H NMR (400 MHz, CDCl₃) δ 8.67 (ddd, J = 4.9 , 2.7, 1.2 Hz,
1H), 8.19 (s, 1H), 7.85 (m, 2H), 7.32 (ddd J = 7.0, 4.9, 1.8 Hz, 1H), 6.93 (q, J =
1.2 Hz, 1H), 4.60 (q, J = 6.6 Hz, 1H), 2.63 (d, J = 1.2 Hz, 3H), 2.20 (br s, 3H),
1.43 (d, J = 6.6 Hz, 3H) ppm. LC/MS (M+1, found = 270.1).

**(S)-N-(1-(2-Methyl-6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)-9H-purin-
15 6-amine:**



6-Chloropurine (26.4 mg, 0.171 mmol), (S)-1-(2-methyl-6-(pyridin-2-yl)thieno-
[2,3-b]pyridin-5-yl)ethanamine (40 mg, 0.148 mmol) and hunig'sbase (38.9 µL,
0.223 mmol) was dissolved in 2 mL of n-butanol and heated to 120 °C overnight.
20 The reaction was cooled to rt and purified by reverse phase chromatography to
afford (S)-N-(1-(2-methyl-6-(pyridin-2-yl)thieno[2,3-b]pyridin-5-yl)ethyl)-9H-

- 42 -

purin-6-amine. ^1H NMR (400 MHz, CDCl_3) δ 12.5 (br s, 1H), 8.78 (br m, 1H), 8.55-7.80 (series of m, 6H), 7.60-7.30 (br m, 1H), 7.26 (m, 1H), 6.89 (br s, 1H), 6.40-6.00 (br m, 1H), 2.60 (br s, 3H), 1.60-1.25 (series of M, 3H). LC/MS (M+1, found = 388.1).

5 Biological Assays

Recombinant expression of PI3Ks

Full length p110 subunits of PI3k α , β and δ , N-terminally labeled with polyHis tag, were coexpressed with p85 with Baculo virus expression vectors in sf9 insect cells. P110/p85 heterodimers were purified by sequential Ni-NTA, Q-HP, Superdex-100 chromatography. Purified α , β and δ isozymes were stored at -20 °C in 20mM Tris, pH 8, 0.2M NaCl, 50% glycerol, 5mM DTT, 2mM Na cholate. Truncated PI3K γ , residues 114-1102, N-terminally labeled with polyHis tag, was expressed with Baculo virus in Hi5 insect cells. The γ isozyme was purified by sequential Ni-NTA, Superdex-200, Q-HP chromatography. The γ isozyme was stored frozen at -80 °C in NaH_2PO_4 , pH 8, 0.2M NaCl, 1% ethylene glycol, 2mM β -mercaptoethanol.

	Alpha	Beta	Delta	gamma
50 mM Tris	pH 8	pH 7.5	pH 7.5	pH 8
MgCl ₂	15 mM	10 mM	10 mM	15 mM
Na cholate	2 mM	1 mM	0.5 mM	2 mM
DTT	2 mM	1 mM	1 mM	2 mM
ATP	1 uM	0.5 uM	0.5 uM	1 uM
PIP ₂	none	2.5 uM	2.5 uM	none
time	1 h	2 h	2 h	1 h
[Enzyme]	15 nM	40 nM	15 nM	50 nM

In vitro enzyme assays.

Assays were performed in 25 μL with the above final concentrations of components in white polypropylene plates (Costar 3355). Phosphatidyl inositol phosphoacceptor, PtdIns(4,5)P₂ P4508, was from Echelon Biosciences. The ATPase activity of the alpha and gamma isozymes was not greatly stimulated by

- 43 -

PtdIns(4,5)P₂ under these conditions and was therefore omitted from the assay of these isozymes. Test compounds were dissolved in dimethyl sulfoxide and diluted with three-fold serial dilutions. The compound in DMSO (1 μ L) was added per test well, and the inhibition relative to reactions containing no compound, with and without enzyme was determined. After assay incubation at rt, the reaction was stopped and residual ATP determined by addition of an equal volume of a commercial ATP bioluminescence kit (Perkin Elmer EasyLite) according to the manufacturer's instructions, and detected using a AnalystGT luminometer.

10 **Human B Cells Proliferation stimulate by anti-IgM**

Isolate human B Cells:

Isolate PBMCs from Leukopac or from human fresh blood. Isolate human B cells by using Miltenyi protocol and B cell isolation kit II. –human B cells were Purified by using AutoMacs.column.

15 *Activation of human B cells*

Use 96 well Flat bottom plate, plate 50000/well purified B cells in B cell proliferation medium (DMEM + 5% FCS, 10 mM Hepes, 50 μ M 2-mercaptoethanol); 150 μ L medium contain 250 ng/mL CD40L –LZ recombinant protein (Amgen) and 2 μ g/mL anti-Human IgM antibody (Jackson ImmunoResearch Lab.#109-006-129), mixed with 50 μ L B cell medium containing PI3K inhibitors and incubate 72 h at 37 °C incubator. After 72h, pulse labeling B cells with 0.5-1 uCi /well ³H thymidine for overnight ~18 h, and harvest cell using TOM harvester.

Human B Cells Proliferation stimulate by IL-4

25 *Isolate human B Cells:*

Isolate human PBMCs from Leukopac or from human fresh blood. Isolate human B cells using Miltenyi protocol – B cell isolation kit. Human B cells were Purified by AutoMacs.column.

Activation of human B cells

30 Use 96-well flat bottom plate, plate 50000/well purified B cells in B cell proliferation medium (DMEM + 5% FCS, 50 μ M 2-mercaptoethanol, 10mM

- 44 -

Hepes). The medium (150 μ L) contain 250 ng/mL CD40L –LZ recombinant protein (Amgen) and 10 ng/mL IL-4 (R&D system # 204-IL-025), mixed with 50 150 μ L B cell medium containing compounds and incubate 72 h at 37 °C incubator. After 72 h, pulse labeling B cells with 0.5-1 uCi /well ³H thymidine
5 for overnight ~18 h, and harvest cell using TOM harvester.

Specific T antigen (Tetanus toxoid) induced human PBMC proliferation assays

Human PBMC are prepared from frozen stocks or they are purified from fresh human blood using a Ficoll gradient. Use 96 well round-bottom plate and plate
10 2×10^5 PBMC/well with culture medium (RPMI1640 + 10% FCS, 50uM 2-Mercaptoethanol, 10 mM Hepes). For IC₅₀ determinations, PI3K inhibitors was tested from 10 μ M to 0.001 μ M, in half log increments and in triplicate. Tetanus toxoid ,T cell specific antigen (University of Massachusetts Lab) was added at 1 μ g/mL and incubated 6 days at 37 °C incubator. Supernatants are collected
15 after 6 days for IL2 ELISA assay , then cells are pulsed with ³H-thymidine for ~18 h to measure proliferation.

GFP assays for detecting inhibition of Class Ia and Class III PI3K

AKT1 (PKBa) is regulated by Class Ia PI3K activated by mitogenic factors (IGF-1, PDGF, insulin, thrombin, NGF, etc.). In response to mitogenic stimuli, AKT1
20 translocates from the cytosol to the plasma membrane

Forkhead (FKHRL1) is a substrate for AKT1. It is cytoplasmic when phosphorylated by AKT (survival/growth). Inhibition of AKT (stasis/apoptosis) - forkhead translocation to the nucleus

FYVE domains bind to PI(3)P. the majority is generated by constitutive action
25 of PI3K Class III

AKT membrane ruffling assay (CHO-IR-AKT1-EGFP cells/GE Healthcare)

Wash cells with assay buffer. Treat with compounds in assay buffer 1 h. Add 10 ng/mL insulin. Fix after 10 min at room temp and image

Forkhead translocation assay (MDA MB468 Forkhead-DiversaGFP cells)

30 Treat cells with compound in growth medium 1 h. Fix and image.

Class III PI(3)P assay (U2OS EGFP-2XFYVE cells/GE Healthcare)

- 45 -

Wash cells with assay buffer. Treat with compounds in assay buffer 1 h. Fix and image.

Control for all 3 assays is 10uM Wortmannin:

AKT is cytoplasmic

5 Forkhead is nuclear

PI(3)P depleted from endosomes

Biomarker assay: B-cell receptor stimulation of CD69 or B7.2 (CD86) expression

Heparinized human whole blood was stimulated with 10 µg/mL anti-IgD
 10 (Southern Biotech, #9030-01). 90 µL of the stimulated blood was then aliquoted per well of a 96-well plate and treated with 10 µL of various concentrations of blocking compound (from 10-0.0003 µM) diluted in IMDM + 10% FBS (Gibco). Samples were incubated together for 4 h (for CD69 expression) to 6 h (for B7.2 expression) at 37 °C. Treated blood (50 µL) was transferred to a 96-well, deep
 15 well plate (Nunc) for antibody staining with 10 µL each of CD45-PerCP (BD Biosciences, #347464), CD19-FITC (BD Biosciences, #340719), and CD69-PE (BD Biosciences, #341652). The second 50 µL of the treated blood was transferred to a second 96-well, deep well plate for antibody staining with 10 µL each of CD19-FITC (BD Biosciences, #340719) and CD86-PeCy5 (BD
 20 Biosciences, #555666). All stains were performed for 15-30 min in the dark at rt. The blood was then lysed and fixed using 450 µL of FACS lysing solution (BD Biosciences, #349202) for 15 min at rt. Samples were then washed 2X in PBS + 2% FBS before FACS analysis. Samples were gated on either CD45/CD19 double positive cells for CD69 staining, or CD19 positive cells for
 25 CD86 staining.

Gamma Counterscreen: Stimulation of human monocytes for phospho-AKT expression

A human monocyte cell line, THP-1, was maintained in RPMI + 10% FBS (Gibco). One day before stimulation, cells were counted using trypan blue
 30 exclusion on a hemocytometer and suspended at a concentration of 1×10^6 cells per mL of media. 100 µL of cells plus media (1×10^5 cells) was then aliquoted per

- 46 -

well of 4-96-well, deep well dishes (Nunc) to test eight different compounds.

Cells were rested overnight before treatment with various concentrations (from 10-0.0003 μ M) of blocking compound. The compound diluted in media (12 μ L) was added to the cells for 10 min at 37 °C. Human MCP-1 (12 μ L, R&D

5 Diagnostics, #279-MC) was diluted in media and added to each well at a final concentration of 50 ng/mL. Stimulation lasted for 2 min at rt. Pre-warmed FACS Phosflow Lyse/Fix buffer (1 mL of 37 °C) (BD Biosciences, #558049) was added to each well. Plates were then incubated at 37 °C for an additional 10-15 min. Plates were spun at 1500 rpm for 10 min, supernatant was aspirated off, 10 and 1 mL of ice cold 90% MEOH was added to each well with vigorous shaking. Plates were then incubated either overnight at -70 °C or on ice for 30 min before antibody staining. Plates were spun and washed 2X in PBS + 2% FBS (Gibco). Wash was aspirated and cells were suspended in remaining buffer. Rabbit pAKT (50 μ L, Cell Signaling, #4058L) at 1:100, was added to each sample for 1 h 15 at rt with shaking. Cells were washed and spun at 1500 rpm for 10 min. Supernatant was aspirated and cells were suspended in remaining buffer. Secondary antibody, goat anti-rabbit Alexa 647 (50 μ L, Invitrogen, #A21245) at 1:500, was added for 30 min at rt with shaking. Cells were then washed 1X in buffer and suspended in 150 μ L of buffer for FACS analysis. Cells need to be 20 dispersed very well by pipetting before running on flow cytometer. Cells were run on an LSR II (Becton Dickinson) and gated on forward and side scatter to determine expression levels of pAKT in the monocyte population.

Gamma Counterscreen: Stimulation of monocytes for phospho-AKT expression in mouse bone marrow

25 Mouse femurs were dissected from five female BALB/c mice (Charles River Labs.) and collected into RPMI + 10% FBS media (Gibco). Mouse bone marrow was removed by cutting the ends of the femur and by flushing with 1 mL of media using a 25 gauge needle. Bone marrow was then dispersed in media using a 21 gauge needle. Media volume was increased to 20 mL and cells were 30 counted using trypan blue exclusion on a hemocytometer. The cell suspension was then increased to 7.5×10^6 cells per 1 mL of media and 100 μ L (7.5×10^5

- 47 -

cells) was aliquoted per well into 4-96-well, deep well dishes (Nunc) to test eight different compounds. Cells were rested at 37 °C for 2 h before treatment with various concentrations (from 10-0.0003 μ M) of blocking compound. Compound diluted in media (12 μ L) was added to bone marrow cells for 10 min at 37 °C.

- 5 Mouse MCP-1 (12 μ L, R&D Diagnostics, #479-JE) was diluted in media and added to each well at a final concentration of 50 ng/mL. Stimulation lasted for 2 min at rt. 1 mL of 37 °C pre-warmed FACS Phosflow Lyse/Fix buffer (BD Biosciences, #558049) was added to each well. Plates were then incubated at 37°C for an additional 10-15 min. Plates were spun at 1500 rpm for 10 min.
- 10 Supernatant was aspirated off and 1 mL of ice cold 90% MEOH was added to each well with vigorous shaking. Plates were then incubated either overnight at -70 °C or on ice for 30 min before antibody staining. Plates were spun and washed 2X in PBS + 2% FBS (Gibco). Wash was aspirated and cells were suspended in remaining buffer. Fc block (2 μ L, BD Pharmingen, #553140) was
- 15 then added per well for 10 min at rt. After block, 50 μ L of primary antibodies diluted in buffer; CD11b-Alexa488 (BD Biosciences, #557672) at 1:50, CD64-PE (BD Biosciences, #558455) at 1:50, and rabbit pAKT (Cell Signaling, #4058L) at 1:100, were added to each sample for 1 h at RT with shaking. Wash buffer was added to cells and spun at 1500 rpm for 10 min. Supernatant was aspirated and
- 20 cells were suspended in remaining buffer. Secondary antibody; goat anti-rabbit Alexa 647 (50 μ L, Invitrogen, #A21245) at 1:500, was added for 30 min at rt with shaking. Cells were then washed 1X in buffer and suspended in 100 μ L of buffer for FACS analysis. Cells were run on an LSR II (Becton Dickinson) and gated on CD11b/CD64 double positive cells to determine expression levels of
- 25 pAKT in the monocyte population.

pAKT in vivo Assay

- Vehicle and compounds are administered p.o. (0.2 mL) by gavage (Oral Gavage Needles Popper & Sons, New Hyde Park, NY) to mice (Transgenic Line 3751, female, 10-12 wks Amgen Inc, Thousand Oaks, CA) 15 min prior to the injection
- 30 i.v (0.2 mLs) of anti-IgM FITC (50 ug/mouse) (Jackson Immuno Research, West Grove, PA). After 45 min the mice are sacrificed within a CO₂ chamber. Blood is

- 48 -

drawn via cardiac puncture (0.3 mL) (1cc 25 g Syringes, Sherwood, St. Louis, MO) and transferred into a 15 mL conical vial (Nalge/Nunc International, Denmark). Blood is immediately fixed with 6.0 mL of BD Phosflow Lyse/Fix Buffer (BD Bioscience, San Jose, CA), inverted 3X's and placed in 37 °C water bath. Half of the spleen is removed and transferred to an eppendorf tube containing 0.5 mL of PBS (Invitrogen Corp, Grand Island, NY). The spleen is crushed using a tissue grinder (Pellet Pestle, Kimble/Kontes, Vineland, NJ) and immediately fixed with 6.0 mL of BD Phosflow Lyse/Fix buffer, inverted 3X's and placed in 37 °C water bath. Once tissues have been collected the mouse is cervically-dislocated and carcass to disposed. After 15 min, the 15 mL conical vials are removed from the 37 °C water bath and placed on ice until tissues are further processed. Crushed spleens are filtered through a 70 µm cell strainer (BD Bioscience, Bedford, MA) into another 15 mL conical vial and washed with 9 mL of PBS. Splenocytes and blood are spun @ 2,000 rpms for 10 min (cold) and buffer is aspirated. Cells are resuspended in 2.0 mL of cold (-20 °C) 90% methyl alcohol (Mallinckrodt Chemicals, Phillipsburg, NJ). MeOH is slowly added while conical vial is rapidly vortexed. Tissues are then stored at -20 °C until cells can be stained for FACS analysis.

Multi-dose TNP immunization

Blood was collected by retro-orbital eye bleeds from 7-8 week old BALB/c female mice (Charles River Labs.) at day 0 before immunization. Blood was allowed to clot for 30 min and spun at 10,000 rpm in serum microtainer tubes (Becton Dickinson) for 10 min. Sera were collected, aliquoted in Matrix tubes (Matrix Tech. Corp.) and stored at -70 °C until ELISA was performed. Mice were given compound orally before immunization and at subsequent time periods based on the life of the molecule. Mice were then immunized with either 50 µg of TNP-LPS (Biosearch Tech., #T-5065), 50 µg of TNP-Ficoll (Biosearch Tech., #F-1300), or 100 µg of TNP-KLH (Biosearch Tech., #T-5060) plus 1% alum (Brenntag, #3501) in PBS. TNP-KLH plus alum solution was prepared by gently inverting the mixture 3-5 times every 10 min for 1 h before immunization. On day 5, post-last treatment, mice were CO₂ sacrificed and cardiac punctured.

- 49 -

Blood was allowed to clot for 30 min and spun at 10,000 rpm in serum microtainer tubes for 10 min. Sera were collected, aliquoted in Matrix tubes, and stored at -70 °C until further analysis was performed. TNP-specific IgG1, IgG2a, IgG3 and IgM levels in the sera were then measured via ELISA. TNP-BSA (Biosearch Tech., #T-5050) was used to capture the TNP-specific antibodies. TNP-BSA (10 µg/mL) was used to coat 384-well ELISA plates (Corning Costar) overnight. Plates were then washed and blocked for 1 h using 10% BSA ELISA Block solution (KPL). After blocking, ELISA plates were washed and sera samples/standards were serially diluted and allowed to bind to the plates for 1 h. Plates were washed and Ig-HRP conjugated secondary antibodies (goat anti-mouse IgG1, Southern Biotech #1070-05, goat anti-mouse IgG2a, Southern Biotech #1080-05, goat anti-mouse IgM, Southern Biotech #1020-05, goat anti-mouse IgG3, Southern Biotech #1100-05) were diluted at 1:5000 and incubated on the plates for 1 h. TMB peroxidase solution (SureBlue Reserve TMB from KPL) was used to visualize the antibodies. Plates were washed and samples were allowed to develop in the TMB solution approximately 5-20 min depending on the Ig analyzed. The reaction was stopped with 2M sulfuric acid and plates were read at an OD of 450 nm.

For the treatment of PI3K δ -mediated-diseases, such as rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases, the compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.

Treatment of diseases and disorders herein is intended to also include the prophylactic administration of a compound of the invention, a pharmaceutical salt thereof, or a pharmaceutical composition of either to a subject (i.e., an animal, preferably a mammal, most preferably a human) believed to be in need of preventative treatment, such as, for example, rheumatoid arthritis, ankylosing

- 50 -

spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases and the like.

The dosage regimen for treating PI3K δ -mediated diseases, cancer, and/or hyperglycemia with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1 mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for all methods of use disclosed herein.

The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.

For oral administration, the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.

The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg.

Injectable preparations, such as sterile injectable aq. or oleaginous suspensions, may be formulated according to the known are using suitable

- 51 -

dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non-irritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose.

For administration, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, acacia, gelatin, sodium alginate, polyvinyl-pyrrolidone, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene

- 52 -

glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.

The pharmaceutical compositions may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.

Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by

- 53 -

liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by
5 reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise
10 be obtained by using active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.

Likewise, the compounds of this invention may exist as isomers, that is compounds of the same molecular formula but in which the atoms, relative to one another, are arranged differently. In particular, the alkylene substituents of the
15 compounds of this invention, are normally and preferably arranged and inserted into the molecules as indicated in the definitions for each of these groups, being read from left to right. However, in certain cases, one skilled in the art will appreciate that it is possible to prepare compounds of this invention in which these substituents are reversed in orientation relative to the other atoms in the
20 molecule. That is, the substituent to be inserted may be the same as that noted above except that it is inserted into the molecule in the reverse orientation. One skilled in the art will appreciate that these isomeric forms of the compounds of this invention are to be construed as encompassed within the scope of the present invention.

25 The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. The salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate,
30 glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,

- 54 -

methansulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 2-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

10 Examples of acids that may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium
15 or with organic bases.

 Also encompassed in the scope of the present invention are pharmaceutically acceptable esters of a carboxylic acid or hydroxyl containing group, including a metabolically labile ester or a prodrug form of a compound of this invention. A metabolically labile ester is one which may produce, for
20 example, an increase in blood levels and prolong the efficacy of the corresponding non-esterified form of the compound. A prodrug form is one which is not in an active form of the molecule as administered but which becomes therapeutically active after some in vivo activity or biotransformation, such as metabolism, for example, enzymatic or hydrolytic cleavage. For a general discussion of prodrugs
25 involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl).
30 Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde

- 55 -

(Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)).

Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and

5 Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use. Esters of a compound of this invention, may include, for example, the methyl, ethyl, propyl, and butyl esters, as well as other suitable esters formed between an acidic moiety and a hydroxyl containing moiety. Metabolically labile esters, may include, for example, methoxymethyl, 10 ethoxymethyl, iso-propoxymethyl, α -methoxyethyl, groups such as α -((C₁-C₄)-alkyloxy)ethyl, for example, methoxyethyl, ethoxyethyl, propoxyethyl, iso-propoxyethyl, etc.; 2-oxo-1,3-dioxolen-4-ylmethyl groups, such as 5-methyl-2-oxo-1,3,dioxolen-4-ylmethyl, etc.; C₁-C₃ alkylthiomethyl groups, for example, methylthiomethyl, ethylthiomethyl, isopropylthiomethyl, etc.; acyloxymethyl 15 groups, for example, pivaloyloxymethyl, α -acetoxymethyl, etc.; ethoxycarbonyl-1-methyl; or α -acyloxy- α -substituted methyl groups, for example α -acetoxylethyl.

Further, the compounds of the invention may exist as crystalline solids which can be crystallized from common solvents such as ethanol, N,N-dimethyl-formamide, water, or the like. Thus, crystalline forms of the compounds of the 20 invention may exist as polymorphs, solvates and/or hydrates of the parent compounds or their pharmaceutically acceptable salts. All of such forms likewise are to be construed as falling within the scope of the invention.

While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or 25 more compounds of the invention or other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.

The foregoing is merely illustrative of the invention and is not intended to 30 limit the invention to the disclosed compounds. Variations and changes which

- 56 -


are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit
5 and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

- 57 -

We Claim:

1. A compound having the structure:



5

or any pharmaceutically-acceptable salt thereof, wherein:

X^1 is $C(R^{10})$ or N;

X^2 is $C(R^6)$ or N;

X^3 is $C(R^7)$ or N;

10 X^4 is $C(R^{10})$ or N;

Y is $N(R^8)$, CR^aR^a , S or O;

R^1 is selected from H, halo, C_{1-6} alk, C_{1-4} haloalk, cyano, nitro, $-C(=O)R^a$, $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-OC(=O)NR^aR^a$, $-OC(=O)N(R^a)S(=O)_2R^a$, $-OC_{2-6}alkNR^aR^a$, $-OC_{2-6}alkOR^a$, $-SR^a$, $-S(=O)R^a$, $-S(=O)_2R^a$, $-S(=O)_2NR^aR^a$, $-S(=O)_2N(R^a)C(=O)R^a$, $-S(=O)_2N(R^a)C(=O)OR^a$, $-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$, $-N(R^a)C(=O)OR^a$, $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$, $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$, $-NR^aC_{2-6}alkOR^a$, $-NR^aC_{2-6}alkCO_2R^a$, $-NR^aC_{2-6}alkSO_2R^b$, $-CH_2C(=O)R^a$, $-CH_2C(=O)OR^a$, $-CH_2C(=O)NR^aR^a$, $-CH_2C(=NR^a)NR^aR^a$, $-CH_2OR^a$, $-CH_2OC(=O)R^a$, $-CH_2OC(=O)NR^aR^a$, $-CH_2OC(=O)N(R^a)S(=O)_2R^a$, $-CH_2OC_{2-6}alkNR^aR^a$, $-CH_2OC_{2-6}alkOR^a$, $-CH_2SR^a$, $-CH_2S(=O)R^a$, $-CH_2S(=O)_2R^b$, $-CH_2S(=O)_2NR^aR^a$, $-CH_2S(=O)_2N(R^a)C(=O)R^a$, $-CH_2S(=O)_2N(R^a)C(=O)OR^a$, $-CH_2S(=O)_2N(R^a)C(=O)NR^aR^a$, $-CH_2NR^aR^a$, $-CH_2N(R^a)C(=O)R^a$, $-CH_2N(R^a)C(=O)OR^a$, $-CH_2N(R^a)C(=O)NR^aR^a$, $-CH_2N(R^a)C(=NR^a)NR^aR^a$, $-CH_2N(R^a)S(=O)_2R^a$, $-CH_2N(R^a)S(=O)_2NR^aR^a$, $-CH_2NR^aC_{2-6}alkNR^aR^a$, $-CH_2NR^aC_{2-6}alkOR^a$, $-CH_2NR^aC_{2-6}alkCO_2R^a$ and

20

25

- 58 -

-CH₂NR^aC₂₋₆alkSO₂R^b; or R¹ is a direct-bonded, C₁₋₄alk-linked, OC₁₋₂alk-linked, C₁₋₂alkO-linked, N(R^a)-linked or O-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6- or 7-membered monocyclic or 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S atom, substituted by 0, 1, 2 or 3 substituents independently selected from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a, -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a, -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a, -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a, -N(R^a)C(=O)OR^a, -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a, -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a, wherein the available carbon atoms of the ring are additionally substituted by 0, 1 or 2 oxo or thioxo groups, and wherein the ring is additionally substituted by 0 or 1 directly bonded, SO₂ linked, C(=O) linked or CH₂ linked group selected from phenyl, pyridyl, pyrimidyl, morpholino, piperazinyl, piperadiny, pyrrolidinyl, cyclopentyl, cyclohexyl all of which are further substituted by 0, 1, 2 or 3 groups selected from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -SR^a, -S(=O)R^a, -S(=O)₂R^a, -S(=O)₂NR^aR^a, -NR^aR^a, and -N(R^a)C(=O)R^a;

R² is selected from a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic or 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or 1 R² substituents, and the ring is additionally substituted by 0, 1, 2 or 3 substituents independently selected from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a, -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a, -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a, -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a, -N(R^a)C(=O)OR^a,

- 59 -

-N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a,
 -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a; or R³ is selected
 from halo, C₁₋₆alk, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a, -C(=O)OR^a,
 -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a,
 5 -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a,
 -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a,
 -S(=O)₂N(R^a)C(=O)NR^aR^a, -NR^aR^a, -N(R^a)C(=O)R^a, -N(R^a)C(=O)OR^a,
 -N(R^a)C(=O)NR^aR^a, -N(R^a)C(=NR^a)NR^aR^a, -N(R^a)S(=O)₂R^a,
 -N(R^a)S(=O)₂NR^aR^a, -NR^aC₂₋₆alkNR^aR^a and -NR^aC₂₋₆alkOR^a;

10 R³ is selected from H, halo, nitro, cyano, C₁₋₄alk, OC₁₋₄alk, OC₁₋₄haloalk,
 NHC₁₋₄alk, N(C₁₋₄alk)C₁₋₄alk, C(=O)NH₂, C(=O)NHC₁₋₄alk, C(=O)N(C₁₋₄alk)C₁₋₄alk,
 N(H)C(=O)C₁₋₄alk, N(C₁₋₄alk)C(=O)C₁₋₄alk and C₁₋₄haloalk;

R⁴ is selected from H, halo, nitro, cyano, C₁₋₄alk, OC₁₋₄alk, OC₁₋₄haloalk,
 NHC₁₋₄alk, N(C₁₋₄alk)C₁₋₄alk, C(=O)NH₂, C(=O)NHC₁₋₄alk, C(=O)N(C₁₋₄alk)C₁₋₄alk,
 15 4alk)C₁₋₄alk, N(H)C(=O)C₁₋₄alk, N(C₁₋₄alk)C(=O)C₁₋₄alk and C₁₋₄haloalk;

R⁵ is, independently, in each instance, H, halo, C₁₋₆alk, C₁₋₄haloalk, or
 C₁₋₆alk substituted by 1, 2 or 3 substituents selected from halo, cyano, OH,
 OC₁₋₄alk, C₁₋₄alk, C₁₋₃haloalk, OC₁₋₄alk, NH₂, NHC₁₋₄alk and N(C₁₋₄alk)C₁₋₄alk;
 or both R⁵ groups together form a C₃₋₆spiroalk substituted by 0, 1, 2 or 3
 20 substituents selected from halo, cyano, OH, OC₁₋₄alk, C₁₋₄alk, C₁₋₃haloalk, OC₁₋₄alk,
 NH₂, NHC₁₋₄alk and N(C₁₋₄alk)C₁₋₄alk;

R⁶ is selected from halo, cyano, OH, OC₁₋₄alk, C₁₋₄alk, C₁₋₃haloalk, OC₁₋₄alk,
 NHR⁹, N(C₁₋₄alk)C₁₋₄alk, -C(=O)OR^a, -C(=O)N(R^a)R^a, -N(R^a)C(=O)R^b and a
 5- or 6-membered saturated or partially saturated heterocyclic ring containing 1, 2
 25 or 3 heteroatoms selected from N, O and S, wherein the ring is substituted by 0, 1,
 2 or 3 substituents selected from halo, cyano, OH, oxo, OC₁₋₄alk, C₁₋₄alk, C₁₋₃haloalk,
 OC₁₋₄alk, NH₂, NHC₁₋₄alk and N(C₁₋₄alk)C₁₋₄alk;

R⁷ is selected from H, halo, C₁₋₄haloalk, cyano, nitro, -C(=O)R^a,
 -C(=O)OR^a, -C(=O)NR^aR^a, -C(=NR^a)NR^aR^a, -OR^a, -OC(=O)R^a, -OC(=O)NR^aR^a,
 30 -OC(=O)N(R^a)S(=O)₂R^a, -OC₂₋₆alkNR^aR^a, -OC₂₋₆alkOR^a, -SR^a, -S(=O)R^a,
 -S(=O)₂R^a, -S(=O)₂NR^aR^a, -S(=O)₂N(R^a)C(=O)R^a, -S(=O)₂N(R^a)C(=O)OR^a,

- 60 -

$-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$, $-N(R^a)C(=O)OR^a$,
 $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$,
 $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$, $-NR^aC_{2-6}alkOR^a$ and $C_{1-6}alk$, wherein the
 $C_{1-6}alk$ is substituted by 0, 1 2 or 3 substituents selected from halo, $C_{1-4}haloalk$,
5 cyano, nitro, $-C(=O)R^a$, $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-OR^a$,
 $-OC(=O)R^a$, $-OC(=O)NR^aR^a$, $-OC(=O)N(R^a)S(=O)_2R^a$, $-OC_{2-6}alkNR^aR^a$,
 $-OC_{2-6}alkOR^a$, $-SR^a$, $-S(=O)R^a$, $-S(=O)_2R^a$, $-S(=O)_2NR^aR^a$, $-S(=O)_2N(R^a)C(=O)R^a$,
 $-S(=O)_2N(R^a)C(=O)OR^a$, $-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$,
 $-N(R^a)C(=O)OR^a$, $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$,
10 $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$ and $-NR^aC_{2-6}alkOR^a$, and the $C_{1-6}alk$ is
additionally substituted by 0 or 1 saturated, partially-saturated or unsaturated 5-,
6- or 7-membered monocyclic rings containing 0, 1, 2, 3 or 4 atoms selected from
N, O and S, but containing no more than one O or S, wherein the available carbon
atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the
15 ring is substituted by 0, 1, 2 or 3 substituents independently selected from halo,
nitro, cyano, $C_{1-4}alk$, $OC_{1-4}alk$, $OC_{1-4}haloalk$, $NHC_{1-4}alk$, $N(C_{1-4}alk)C_{1-4}alk$ and
 $C_{1-4}haloalk$; or R^7 and R^8 together form a $-C=N-$ bridge wherein the carbon atom
is substituted by H, halo, cyano, or a saturated, partially-saturated or unsaturated
5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selected
20 from N, O and S, but containing no more than one O or S, wherein the available
carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein
the ring is substituted by 0, 1, 2, 3 or 4 substituents selected from halo, $C_{1-6}alk$,
 $C_{1-4}haloalk$, cyano, nitro, $-C(=O)R^a$, $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$,
 $-OR^a$, $-OC(=O)R^a$, $-OC(=O)NR^aR^a$, $-OC(=O)N(R^a)S(=O)_2R^a$, $-OC_{2-6}alkNR^aR^a$,
25 $-OC_{2-6}alkOR^a$, $-SR^a$, $-S(=O)R^a$, $-S(=O)_2R^a$, $-S(=O)_2NR^aR^a$, $-S(=O)_2N(R^a)C(=O)R^a$,
 $-S(=O)_2N(R^a)C(=O)OR^a$, $-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$,
 $-N(R^a)C(=O)OR^a$, $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$,
 $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$ and $-NR^aC_{2-6}alkOR^a$; or R^7 and R^9
together form a $-N=C-$ bridge wherein the carbon atom is substituted by H, halo,
30 $C_{1-6}alk$, $C_{1-4}haloalk$, cyano, nitro, OR^a , NR^aR^a , $-C(=O)R^a$, $-C(=O)OR^a$,
 $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-S(=O)R^a$, $-S(=O)_2R^a$ or $-S(=O)_2NR^aR^a$;

- 61 -

R^8 is H, $C_{1-6}alk$, $C(=O)N(R^a)R^a$, $C(=O)R^b$ or $C_{1-4}haloalk$;

R^9 is H, $C_{1-6}alk$ or $C_{1-4}haloalk$;

R^{10} is independently in each instance H, halo, $C_{1-3}alk$, $C_{1-3}haloalk$ or cyano;

5 R^{11} is selected from H, halo, $C_{1-6}alk$, $C_{1-4}haloalk$, cyano, nitro, $-C(=O)R^a$, $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-OC(=O)NR^aR^a$, $-OC(=O)N(R^a)S(=O)_2R^a$, $-OC_{2-6}alkNR^aR^a$, $-OC_{2-6}alkOR^a$, $-SR^a$, $-S(=O)R^a$, $-S(=O)_2R^b$, $-S(=O)_2NR^aR^a$, $-S(=O)_2N(R^a)C(=O)R^a$, $-S(=O)_2N(R^a)C(=O)OR^a$, $-S(=O)_2N(R^a)C(=O)NR^aR^a$, $-NR^aR^a$, $-N(R^a)C(=O)R^a$, $-N(R^a)C(=O)OR^a$,
 10 $-N(R^a)C(=O)NR^aR^a$, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$, $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$ and $-NR^aC_{2-6}alkOR^a$;

R^a is independently, at each instance, H or R^b ; and

R^b is independently, at each instance, phenyl, benzyl or $C_{1-6}alk$, the phenyl, benzyl and $C_{1-6}alk$ being substituted by 0, 1, 2 or 3 substituents selected
 15 from halo, $C_{1-4}alk$, $C_{1-3}haloalk$, $-OC_{1-4}alk$, $-NH_2$, $-NHC_{1-4}alk$ and $-N(C_{1-4}alk)C_{1-4}alk$.

2. A method of treating rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases and autoimmune
 20 diseases, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, skin complaints with inflammatory components, chronic inflammatory conditions, autoimmune diseases, systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples
 25 sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions and hypersensitivity, comprising the step of administering a compound according to Claim 1.

3. A method of treating cancers, which are mediated, dependent on or
 30 associated with p110 δ activity, comprising the step of administering a compound according to Claim 1.

- 62 -

4. A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically-acceptable diluent or carrier.